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                                          ABSTRACT 
Characterization of M-cadherin’s Role in Regulating Apoptosis and 
Myogenic Differentiation of Myoblasts by Interacting with Key 
Components of Canonical Wnt Signaling 
                                                           Yan Wang 
Activation, proliferation, and differentiation of satellite cells are the basic means for adult 
muscle regeneration. Apoptosis is concurrent to differentiation of satellite cells and 
dysregulated apoptosis contributes to the occurrence and progression of certain 
muscular dystrophies. This study investigated the role of M-cadherin-mediated signaling 
in regulating apoptosis versus survival of myoblasts during the process of myogenic 
differentiation. Inhibition of M-cadherin expression by RNAi (RNA interference) in 
confluent C2C12 myoblasts sensitized the cells to mitochondria-associated intrinsic 
apoptosis induced by either cell confluence or serum starvation. Manipulation of M-
cadherin signaling regulated the Glycogen Synthase Kinase-3β (GSK-3β) activity via 
phosphoinositide-3 kinase (PI3K)/Akt pathway. Overexpession of wild-type (WT) GSK-
3β in confluent C2C12 myoblasts sensitized the cells to apoptotic insults, while GSK-3β 
inhibition attenuated apoptosis and partially rescued the myogenic differentiation 
impaired by M-cadherin RNAi in both C2C12 myoblasts and Syndecan-4-positive 
primary myoblasts. These data suggest that M-cadherin-mediated signaling protects 
myoblasts against mitochondria-associated intrinsic apoptosis during myogenic 
differentiation via PI3K/Akt/GSK-3β pathway. We further examined the role of M-
cadherin in regulating the N-terminal phosphorylation status of β-catenin and the effect 
of this regulation on myoblast fate specification. M-cadherin RNAi enhanced the GSK-
3β-dependent phosphorylation of β-catenin at N-terminus which can be reversed by 
GSK-3β inhibition via LiCl treatment. N-terminus unphosphorylated β-catenin was more 
responsive to LiCl treatment.  In addition, M-cadherin RNAi led to an increase in 
TCF/LEF transcription activity but significantly abrogated the myogenic differentiation 
induced by LiCl or Wnt-3a treatment. β-catenin RNAi also blocked the myogenic 
induction by LiCl or Wnt-3a. Although forced expression of a phosphorylation-resistant 
mutated β-catenin (S33Y-β-catenin) failed to increase myogenic differentiation, it 
partially rescued the impaired myogenic differentiation and attenuated the apoptosis 
caused by M-cadherin RNAi. These data indicate that M-cadherin-mediated signaling 
plays a positive role in maintaining a cytosolic pool of signaling-active N-terminal 
unphosphorylated β-catenin, which is critical for the TCF/LEF-independent myogenesis-
promoting effect of canonical Wnt signaling. Our findings in this research identify a 
novel role of M-cadherin in regulating myoblasts survival and differentiation and provide 
a potentially novel molecular mechanism for the regulation of adult muscle regeneration.  
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                                  SPECIFIC AIMS 
     Differentiation of satellite cells and fusion into myotubes is the basic means for 
adult muscle regeneration (1; 2). Apoptosis is a concurrent event to myogenic 
differentiation, that is, a substantial portion of cells die of apoptosis as the majority of 
cells differentiate and fuse into myotubes (3; 4). The molecular mechanism by which the 
myoblasts make the life versus the death decision remains unclear. Cadherins are 
calcium-dependent homophilic cell adhesion molecules forming adherens junctions and 
desmosomal junctions between cells. M-cadherin is a member of classical cadherins 
that is specifically expressed in skeletal muscle and certain neural tissues (5; 6). It is 
reported that M-cadherin mediates the cell-cell fusion and is required for myogenic 
differentiation (7; 8). However, its role in regulating myoblast survival/apoptosis has 
never been addressed. 
    β-catenin/canonical Wnt signaling plays a critical role in myogenesis and adult 
muscle regeneration (9; 10). β-catenin is an essential mediator for canonical Wnt 
signaling as well as a key adaptor protein that connects M-cadherin to α-catenin and the 
actin cytoskeleton system (11). Cadherin has an established role as a β-catenin 
signaling inhibitor by either mechanical sequestration or transcriptional suppression (12-
14). A recent study showed that E-cadherin in colon carcinoma cells could directly 
suppress β-catenin activity by promoting its phosphorylation at the N-terminus by GSK-
3β (15). Sequential phosphorylation of β-catenin at the N-terminus by CKIα and GSK-3β 
results in its recognition by β-TrCP and subsequent degradation in the proteasome (16). 
However, the regulatory effect of M-cadherin on phosphorylation status of β-catenin N-
xiv 
 
terminus and the impact of this regulation on myogenic differentiation remains to be 
elucidated.  
The central hypothesis of this project is that M-cadherin-mediated signaling 
regulates the biological behavior and fate of myoblasts by (i) protecting 
myoblasts against mitochondrial dysfunction-associated intrinsic apoptosis via 
the PI3K/Akt/GSK-3β pathway and (ii) attenuating GSK-3β-dependent phosphory-
lation of β-catenin at N-terminus and maintaining a signaling-active 
unphosphorylated β-catenin, which is critical to canonical Wnt signaling. 
This hypothesis will be tested by the following specific aims. 
Specific Aim 1: To determine if M-cadherin-mediated signaling may protect C2C12 
myoblasts against apoptosis and if this protective effect is mediated by the 
PI3K/Akt/GSK-3β pathway.   
Hypothesis 1.1: Knockdown of M-cadherin expression by RNAi will sensitize 
myoblasts to mitochondria-associated intrinsic apoptosis induced by either cell 
confluence or serum starvation while activation of M-cadherin-mediated signaling 
has the opposite effect, indicating that M-cadherin protects myoblast against 
apoptosis.  
Hypothesis 1.2:  Knockdown of M-cadherin expression by RNAi will decrease Akt 
activation and attenuate the Akt-dependent inhibitory phosphorylation of GSK-3β. 
Conversely activation of M-cadherin-mediated signaling will have the opposite 
effect. In addition, the GSK-3β inhibition by M-cadherin is PI3K dependent.  
xv 
 
Hypothesis 1.3: Overexpression of GSK-3β will sensitize myoblasts to apoptosis 
induced by either cell confluence or serum starvation while inhibition of GSK-3β has 
the opposite effect, indicating activation of GSK-3β promotes apoptosis of 
myoblasts. 
Hypothesis 1.4: Inhibition of GSK-3β activity will rescue the apoptotic and 
myogenic phenotype of myoblast caused by M-cadherin RNAi, indicating the 
protective effect against apoptosis by M-cadherin is mediated by GSK-3β 
suppression.  
 
Specific Aim 2: To determine if M-cadherin-mediated signaling may protect 
primary muscle progenitor cells against apoptosis and if this protective effect is 
mediated by GSK-3β activity.   
        Hypothesis 2.1: Knockdown of M-cadherin expression by RNAi in primary 
progenitor cells will exacerbate apoptosis and impair the myogenic differentiation in 
specific population of primary progenitor cells. 
Hypothesis 2.2: Inhibition of GSK-3β activity by certain chemical inhibitors will 
rescue the apoptotic and myogenic phenotype caused by M-cadherin RNAi in 
primary muscle progenitor cells; 
Specific Aim 3: To determine if M-cadherin modulates phosphorylation status of 
β-catenin N-terminus and the effect of this modulation on myoblast fate 
specification.   
xvi 
 
Hypothesis 3.1:  Knockdown of M-cadherin expression by RNAi will enhance 
phosphorylation of β-catenin N-terminus by GSK-3β while inhibition of GSK-3β by a 
chemical inhibitor will rescue this effect, indicating that M-cadherin regulates 
phosphorylation status of β-catenin at N-terminus in a GSK-3β activity-dependent 
manner. 
Hypothesis 3.2: Chemical inhibition GSK-3β will promote myogenic differentiation 
while M-cadherin RNAi will abrogate this effect, indicating M-cadherin is required for 
GSK-3β inhibition-induced increase in myogenic differentiation. 
Hypothesis 3.3: β-catenin RNAi or treatment with canonical Wnt inhibitor will 
effectively reverse the myogenic induction caused by chemical inhibition of GSK-3β, 
indicating the phenotype of myoblasts induced by GSK-3β inhibition is mediated by 
β- catenin/canonical Wnt signaling. 
Hypothesis 3.4:  Transfection of a phosphorylation-resistant mutant form of β- 
catenin will rescue the myoblast phenotype caused by M-cadherin RNAi, indicating 
that M-cadherin’s role in promoting myogenic differentiation is at least partially 
mediated by the modulation of the phosphorylation status of β-catenin N-terminus.  
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CHAPTER 1: 
BACKGROUND AND SIGNIFICANCE 
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1.1. Satellite cells and muscle regeneration 
1.1.1. Satellite cells: heterogeneity and molecular markers. Satellite cells 
were first identified in 1961 by Mauro (1). They are named after their typical 
position in muscles that is between the basal lamina and the sarcolemma of their 
associated muscle fibers. Satellite cells are considered as the primary source of 
stem cells for adult muscle regeneration and plays a crucial role in mediating the 
postnatal growth of muscle (2). Satellite cells are heterogeneous in their 
embryological origin, fiber association, and biological behavior when culture in vitro 
(3-5).  Several markers have been used to identify the majority of satellite cells, 
including syndecan-3 and -4, integrin-α7, CD34, M-cadherin, c-met, Pax7, Myf5, 
etc (4). Many groups have separated different subpopulations of satellite cells 
using FACS (fluorescence-activated cell sorting) based on the expression of 
surface markers. For example, the Olwin lab reported that syndecan-4 is a reliable 
marker for muscle-derived stem cells (6). Wagers’ group showed that a population 
of satellite cells that are CD45-Sca-Mac1-CXCR4+ 1integrin+ are more efficient in 
engrafting into dystrophic muscles compared with control populations without this 
marker combination when both transplanted into host muscles (7).  
1.1.2. Activation, proliferation and differentiation of satellite cells. In the 
adult muscle, under normal physiological resting state, satellite cells are quiescent 
both mitotically and metabolically. In response to stress stimuli such as muscle 
injury or increased workload, the quiescent satellite cells can be activated and 
move out of their niche to the basal lamina and re-enter the cell cycle with Pax7 
and Myf5 expressed. The descendents of activated satellite cells are defined as 
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myoblasts that will proliferate and undergo multiple divisions and differentiate and 
fuse to form multinucleated myofibers, which is a critical process for post-injury 
muscle regeneration (8; 9). The mechanism that explains how satellite cells are 
activated in response to a range of stimuli remains largely unknown. Various 
growth factors and secondary messengers, such as hepatocyte growth factor 
(HGF) (10), fibroblast growth factor (FGF) (11; 12) and nitric oxide (NO) (13) are 
thought to play important roles in the activation of satellite cells. After being 
activated, muscle regulatory factors (MRFs) are expressed in satellite cells at 
different stages of myogenesis (14): Myf5 is expressed in both quiescent and 
activated satellite cells and proliferating myoblasts. MyoD expression start as the 
satellite cell is activated. The expression of myogenin occurs in myoblasts that exit 
cell cycle and marks the first commitment step for myogenic differentiation. As the 
cell cycle inhibitor p21 accumulates in the nuclei, terminal differentiation is 
accomplished with the expression of contractile and associated proteins such as 
myosin heavy chain (MyHC) and Troponin T (15). The muscle cells fuse to each 
other to form myotubes in vitro or myofibers in vivo (16; 17) (Figure 1).  
 
Figure 1. Schematic process of satellite cell myogenesis (14). 
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The C2C12 cell line is a subclone (produced by H. Blau, (18)) of the mouse 
myoblast cell line established by D. Yaffe and O. Saxel (19). When being cultured 
in vitro in growth medium at a low cell density, the C2C12 myoblasts are capable 
of proliferating for self-renewal. When they obtain confluence or when they are 
cultured in low-serum conditions, they differentiate spontaneously and rapidly, fuse 
with each other, and form contractile myotubes and produce characteristic muscle 
proteins. Thus, the C2C12 myoblast is an established and well-studied in vitro 
model for activated myoblasts (18).       
1.1.3. Satellite cell dysfunction-related muscular dystrophic disorders. In 
mouse, fast myofibers contain about 300 myonuclei and they are associated with 
5-12 satellite cells per fiber. In a slow myofibers, there are about 450 myonuclei 
associated with about 30 satellite cells (20). Studies have demonstrated that 
satellite cells undergo an asymmetrical division, which generates a replacement 
satellite cell and a daughter cell that is committed to a myogenic fate (21). Thus, 
satellite cells may maintain a constant pool during the process of muscle 
regeneration (22). The total number of satellite cells decreases in both fast and 
slow muscle fibers with aging in rodents.  At birth, satellite cells account for about 
32% of total muscle nuclei, but the number drops to less than 5% in adult muscle 
(23). A significant decline in the number of M-cadherin-positive satellite cells in 
human muscle during aging was also reported (24). Interestingly the proliferation 
and regenerative capacity of satellite cells in old skeletal muscle could be restored 
when exposed to a young systemic environment by parabiotic pairings of young 
and old animals, indicating that in addition to intrinsic potential of the cells, the 
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extrinsic microenvironment, the niche where satellite cells reside is very important 
in regulating the functional status of satellite cells (25; 26). 
          The impaired capability of proliferation and differentiation of satellite cells is 
regarded as one of the major factors that contribute to the occurrence and 
progression of certain muscle wasting conditions, such as sarcopenia and 
Duchene Muscular Dystrophy. Sarcopenia is a Greek term that means lack of 
flesh. This is an aging-associated decline of muscle mass, quality and performance 
which leads to frailty in the elderly (27; 28). Sarcopenia begins in the fourth decade 
of life and accelerates after the age of 70. The total cross section area of skeletal 
muscle decreases by up to 40% at the age of 80s compared with that at the age of 
20s (29).  Sarcopenia has multiple detrimental effects and leads to physical 
disability, loss of independence, a variety of metabolic disorders and increased 
morbidities. The estimated health care costs directly related to sarcopenia was 
about 18.5 billion dollars in US in 2000 (30). Both number and functionality of 
satellite cells decline in aged people with sarcopenia (31; 32). Another pathological 
condition that is associated with decreased or even exhausted number and 
functionality of satellite cells is Duchenne Muscular Dystrophy (DMD), which is a 
lethal recessive x-linked muscular dystrophy. The mutation occurs in the gene 
coding for dystrophin. Dystrophin is a cytoplasmic protein, a vital component of 
dystroglycan complex (DGC) which connects the cytoskeleton of a muscle fiber to 
the surrounding extracellular matrix (ECM) via cell membrane. Thus the DGC is 
critical for cell integrity, signaling and muscle function. Without DGC, the muscles 
undergo repeated injury and regeneration due to the mechanical stress during 
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contraction, which results in rapid exhaustion of satellite cells and rapid 
progression of muscle degeneration, eventually leads to loss of ambulation, 
paralysis and death. DMD is one of the most prevalent muscular dystrophies and 
affects one out of 3500 males in USA (33).  
 
1.2. β-catenin/canonical Wnt signaling and its role in muscle 
regeneration.  
1.2.1. β-catenin/canonical Wnt signaling and its regulation by GSK-3β. 
Wnts are secreted extracellular proteins that trigger a wide range of cellular 
responses upon receptor binding and activation (34). Wnt signaling can be broadly 
categorized as canonical or noncanonical pathways. Both require the Wnt ligation 
of Frizzled receptor (Figure 2). But the noncanonical Wnt pathway is β-catenin-
independent, mediated by the intracellular calcium ion, JNK, and PKC, which leads 
to signaling events such as activation of NFAT transcription and planar cell polarity 
(35), which is not the focus of this review.  Canonical Wnt pathway is initiated by 
the binding of Wnts to two cell surface proteins, one is the Frizzled receptor, the 
other is lipoprotein receptor-related protein-5 and 6 (LRP5/6).  Ligation of Wnts 
triggers phosphorylation of LRP5/6’s cytoplasmic tail and recruits Disheveled 
protein to the plasma membrane, followed by recruitment of Axin and GSK-3β to 
Disheveled, which inactivates the so-called destruction complex for β-catenin (36). 
β-catenin belongs to the armadillo family of proteins, which have a central domain 
consisting a repeating 42 amino acid motif termed as the “arm repeat” (37). X-ray 
crystallographic analysis shows that the 12 arm repeats in the central domain of β-
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catenin form a superhelix of helices. This creates a long, positively charged groove 
(38) that is capable of interacting with many negatively charged ligands, such as 
cadherin, the Axin/APC destruction complex, and the TCF/LEF(T cell 
factor/lymphoid enhancer factor) transcription factors (Figure 3). In the absence of 
Wnt ligands, cytosolic β-catenin is recruited to a destruction complex composed of 
Axin, adenomatous polyposis coli (APC), and Glycogen Synthase Kinase-3β 
(GSK-3β). The N-terminus of β-catenin is phosphorylated sequentially by axin-
bound casein kinase Iα (CK1α) at serine 45, and by GSK-3β at serine 33/37 and 
threonine 41 (39) (Figure 2 and Figure 3). The N-terminal phosphorylated β-
catenin is recognized by β-TrCP(β-transducin repeat-containing protein), a 
component of the E3 ubiquitin ligase complex, which results its rapid degradation 
in 26S proteasome (40). So without Wnt signaling, the level of β-catenin is kept low 
by degradation of cytoplasmic β-catenin. Thus, the transcription factors LEF1 and 
TCF interact with Grouchos in the nucleus to repress Wnt-specific transcription. In 
the presence of Wnt ligands, LRP5/6 surface receptors are phosphorylated by 
CKIγ and GSK-3β, Dishevelled is recruited to the plasma membrane which leads 
to dissociation of the destruction complex, resulting in stabilization and 
accumulation of cytosolic β-catenin.  β-catenin translocates into nucleus and 
displaces Grouchos and forms a transcriptionally active complex. The TCF/LEF 
transcription factors then induce Wnt-specific target gene expression (36) (Figure 
2). Therefore, the key regulatory factor in β-catenin signaling is its stabilization and 
accumulation in the cytosol (41-43).  
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              Figure 2. Dual role of β-catenin in cadherin and canonical  
              Wnt signaling pathways (erbiotek.erciyes.edu.tr/dosyalar/Molecular_  
                       mechanisms_of_pluripotency.ppt) 
 
 
 
 
 
            
             Figure 3. Regulatory residues at N-terminus and binding  
             sites in β-catenin protein. 
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1.2.2. The role of β-catenin/canonical Wnt signaling in regulating muscle 
regeneration. Canonical Wnt signaling regulates many cellular events including 
proliferation, differentiation, and morphogenesis. Dysregulated Wnt signaling has 
been associated with cancers especially colon cancers, tissue fibrosis, 
osteoporosis, etc (34; 36). In skeletal muscle, it was demonstrated that in response 
to muscle injury, the muscle resident CD45+ stem cells were mobilized to enter cell 
cycle for self-expansion. Furthermore, activation of Wnt signaling effectively 
induces the myogenic specification of these muscle resident CD45+ stem cells 
(44). It was also shown that activation of β-catenin signaling induces myogenesis 
and inhibits adipogenesis in mesenchymal stromal cells (MSC) (45). The 
expression of β-catenin and activation of Wnt signaling in activated satellite cells 
promotes their proliferation and self-renewal (46; 47).  More importantly, by 
working collaboratively with Notch signaling, Wnt signaling is critical for myogenic 
differentiation. Upon muscle injury, the expression of Notch signaling components 
(Delta-1, Notch-1, and active Notch) is up-regulated in activated satellite cells. 
Increased Notch signaling promotes the transition of activated satellite cells to 
highly proliferative myoblasts. However, the elevated Notch signaling also prevents 
the occurrence of myogenic differentiation (48). As the cells start to commit to 
myogenic differentiation, there is a transition from Notch signaling to Wnt signaling 
in myogenic precursor cells with an increase in both Wnt expression in tissue and 
Wnt responsiveness in progenitor cells (49). On the other hand, hyperactivation of 
Wnt signaling turns myogenic progenitor cells into a fibrotic lineage and results in 
muscle fibrosis (50).  
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             Recent studies have added novel information to the mechanism of   β-
catenin signaling and they show more clearly how it regulates myogenesis. It was 
reported that upon Wnt stimulation, the N-terminal unphosphorylated β-catenin is 
more responsive, and accumulates in nuclei (51; 52), Additionally, the N-terminal 
unphosphorylated β-catenin is more signaling-active and plays a major role in 
mediating canonical Wnt signaling (53). Thus the GSK-3β-dependent 
phosphorylation of β-catenin at the N-terminus alone might be sufficient to inhibit 
β-catenin activity by preventing its nuclear translocation via cytosolic 
sequestration, without affecting its stability in certain types of cells and tissues. 
Furthermore, in addition to its classical binding partner in nuclei, TCF/LEF, β-
catenin was found to interact with I-mfa (an inhibitor of the MyoD family of muscle 
MRFs) in muscle progenitor cells. This interaction relieved the transcription activity 
suppression and cytosolic sequestration of MRFs caused by the binding of I-mfa 
(54). In addition, β-catenin has been shown to  directly bind to MyoD and this 
binding enhances MyoD transcription activity that is necessary for myogenic 
differentiation, whereas TCF/LEF activity is dispensable for this effect (55). These 
findings suggest that β-catenin/canonical Wnt signaling may promote myogenesis 
independent of TCF/LEF transcription activity.  
 
1.3.  Apoptosis and its role in muscle remodeling and satellite cell 
biology 
1.3.1. Apoptosis and its molecular regulation. Apoptosis is a systemic process 
of programmed cell death that is important for normal tissue morphogenesis and 
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homeostasis during development. Apoptosis is a genetically predetermined 
mechanism that may be initiated by three different molecular pathways. Firstly, the 
extrinsic death receptor-mediated pathway of apoptosis is triggered by the ligand 
binding-induced activation of death receptors at the cell surface. The death 
receptors include the tumor necrosis factor (TNF) receptor-1, CD95/Fas (the 
receptor of CD95L/FasL) and TNF-related apoptosis inducing ligand (TRAIL) 
receptors-1 and 2. The ligation of death receptors leads to their homo-trimerization 
and the recruitment and oligomerization of the cytoplasmic adapter molecule 
FADD (Fas-associating death domain-containing protein) within the death-inducing 
signaling complex (DISC). Oligomerized FADD binds to caspases-8 and 10, 
resulting in their dimerization and activation (56). The second pathway is intrinsic 
mitochondrial-associated pathway which is activated in response to extracellular or 
intracellular insults such as DNA damage, and characterized by the occurrence of 
mitochondrial outer membrane permeabilization (MOMP), which is marked by the 
release of a number of proteins that normally exist within the intermembrane space 
(IMS) into an extramitochondrial compartment (cytosol and nuclei). Many proteins 
released from mitochondria including Cyt c (cytochrome c), AIF (apoptosis 
inducing factor), EndoG (endonuclease), and Smac/DIABLO (second 
mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding 
protein with a low isolelectric point) are proapoptotic in the cytosol or nucleus (57). 
Cyt c, a component of the mitochondrial respiratory chain, interacts with its adaptor 
molecule Apaf-1 (apoptosis protease activating factor 1) in cytosol and triggers the 
ATP/dATP-dependent oligomerization of Apaf-1. Oligomerized Apaf-1 binds to 
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procaspase-9, leading to the formation of the caspases-9 activation complex 
named as apoptosome (58) that cleaves procaspase-9 into its active form. This in 
turn cleaves and activates the executioner caspases, such as caspases-3 and -7, 
leading to the cleavage of caspases substrate proteins and resulting in the 
biological and morphological features of programmed cell death. The third pathway 
is also intrinsic and associated with endoplasmic reticulum (ER) stress, which 
includes disruption of ER calcium homeostasis and accumulation of excessive 
proteins in ER.  Caspase-12 is activated by ER stress as an initiator caspase that 
is responsible to the cascade of executioner caspases activation (59). However, 
the precise mechanism remains to be elucidated.  
1.3.2. Apoptosis in muscle remodeling and satellite cell biology. Dysregulated 
apoptosis contributes to the occurrence and progression of many pathological 
conditions including autoimmune diseases, cancer, neurodegenerative diseases, 
and certain cardiovascular diseases (56; 60). In skeletal muscle, accumulating 
evidence suggests that apoptosis plays an important role in muscle remodeling. 
Elevated apoptotic signaling has been detected in various muscle wasting 
conditions caused by disuse, denervation, and aging (61-63). As for the satellite 
cells, their number in aged muscle declines due to increased apoptotic depletion in 
aged muscle  (64). Moreover, when cultured in vitro, muscle progenitor cells 
isolated from aged muscle are more sensitive to apoptotic insults compared with 
the cells isolated from young muscles (65). Elimination of muscle progenitor cells 
by apoptosis also contributes to the low regeneration capability of dystrophic 
muscles and the poor outcomes of stem-cell-based therapeutic strategies (66-69). 
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In addition, in vitro culture of myoblasts has shown that apoptosis is concurrent 
with myogenic differentiation (70).  
 
1.4. Cadherin and its role in apoptosis, β-catenin/canonical Wnt signaling 
and muscle regeneration. 
1.4.1. Cadherins and their roles in regulating cell survival. Cadherins are Ca2+-
dependent cell adhesion molecules that are the key components of several cell-cell 
adhesion complexes including adherens junctions and desmosomes. The cadherin 
superfamily consists of different subfamilies: classic cadherins (type I & type II), 
desmosomal cadherins, protocadherins, and other related cadherins (71; 72). The 
classical cadherins are composed of a highly conserved carboxy-terminal 
cytodomain, a single-pass transmembrane domain, and five extracellular cadherin-
motif subdomains (C1-C5) with a conserved His-Ala-Val (HAV) sequence in C1 of 
type I classic cadherins. They mediate homophilic, Ca2+-dependent cell-cell 
adhesion. In the absence of calcium, the cadherin structure is disorganized and 
incapable of participating in adhesion. As calcium concentration  increases, the 
C1-C5 subdomains become organized (C1, which has the lowest affinity for 
calcium, becomes organized last) and the cadherin ectodomains become rigid and 
competent to participate in cis-dimerization and also trans-dimerization as the 
calcium concentration increases (73; 74). In addition, to establishing strong 
adhesion, classical cadherins need to link to the cytoskeleton. This is mediated by 
binding of the cytoplasmic tail of classical cadherin to β-catenin, which in turn binds 
to α-catenin. α-catenin bridges the cadherin-β-catenin complex to the actin 
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cytoskeleton either directly or indirectly via actin-binding proteins such as α-actinin 
or profiling, thus coupling ectodomain interactions to dynamic intracellular tensile 
forces (72). 
        The accumulating evidence shows that cadherin-mediated cell-cell adhesion 
provides a survival signal in a variety of cell types, including neural cells (75), 
endothelial cells (76; 77), ovarian cells (78; 79), granulosa cells (80), enterocytes 
(81), vascular smooth muscle cells (82) and many tumor cells (83-87). Cadherins 
mediate cell survival via several possible mechanisms as revealed by studies on 
different cell types. One of the most important pathways that mediate cadherins’ 
survival-promoting effect is PI3K/Akt, which can be activated by different types of 
cadherins, and results in the phosphorylation and inactivation of the pro-apoptotic 
protein Bad, and the stabilization of the anti-apoptotic protein Bcl-2 (80; 85; 87; 
88). This cadherin-dependent Akt activation appears to be ligand/growth-factor 
independent (86-88). Another candidate pathway is fibroblast growth factor 
receptor (FGF-R) which also has a HAV motif in its extracellular domain. 
Cadherins like N-cadherin has an IDPVNGQ motif in ECD4 which can bind to the 
HAV motif of FGF-R. Therefore, by forming heterodimers with FGF-R through the 
binding of these two motives, cadherins can activate FGF-R and mediate cell 
survival (76; 89). Cadherin may also regulate cell survival via β-catenin. However, 
the role of β-catenin in cell survival/death is cell-type specific. β-catenin is survival-
promoting in some types of cells including epithelial cells cultured in suspension 
(90), fibroblasts (91), and an embryonic liver culture system (92), but apoptosis-
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promoting in other types of cells, including COS7 and 293 cells (93), as well as 
several cancer cell lines (94).  
1.4.2. The role of cadherins in regulating myogenesis. Cadherins also play an 
important role in regulating myogenesis. Gurdon et al reported that during 
myogenesis, the “community effect”, occurs, whereby cells must contact a 
sufficient number of like neighbors if they are undergoing coordinate differentiation 
within a developing tissue (95; 96). N-cadherin is expressed throughout the 
process of avian and murine myogenesis, and antibodies that neutralize N-
cadherin inhibit differentiation of myogenic cells (97-99). Conversely, recombinant 
cadherin ectodomains coupled to planar substrates or beads, which are able to 
induce lateral clustering of cadherins at sites of attachment, facilitate the 
recruitment of catenin to cadherin and induce the reorganization of actin 
cytoskeleton system thus allow myoblasts to differentiate at low cell density, in a 
similar way to that observed in cells cultured on plastic substrate at high cell 
density (100; 101).  As for the signaling events downstream to cadherins leading to 
myogenic gene programming, it’s reported that cadherin ligation results in up-
regulation of p21 and p27 cyclin-dependent kinase inhibitors and cell cycle arrest, 
and increases expression of myogenin, and muscle-specific sarcomeric proteins. 
In addition, cadherin ligation can also regulate the reorganization of actin 
cytoskeleton by altering the activation status of Rho GTPases (activating RhoA but 
suppressing Rac1 and Cdc42), the established regulators of actin dynamics (99-
101).   
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1.4.3. The role of cadherins in regulating β-catenin transcription activity. 
Sadot reported that in Chinese hamster ovary (CHO) and SW480 colon carcinoma 
cell lines, the binding of β-catenin to the cadherin cytoplasmic tail either in the 
membrane, or in the nucleus, can inhibit β-catenin degradation and efficiently block 
its transactivation (102). Gottardi reported that expression of wild-type E-cadherin 
significantly inhibits the growth of colorectal tumor cell line via inhibiting β-
catenin/TCF gene promoter activity in an adhesion-independent manner (103). 
Similarly, Stockinger demonstrated that forced expression of E-cadherin in both 
fibroblasts and epithelial cells induces cell cycle arrest by inhibiting β-catenin 
transcriptional activity (104). Gauthier-Rouviere’s group reported that N-cadherin-
dependent cell-cell contact activates muscle-specific promoters and RhoA in 
C2C12 cells. RhoA activity is required for β-catenin recruitment to intercellular 
adhesions sites (105). Kuphal and Behrens (106) reported that in DLD-1 colorectal 
cancer cells, inhibition of E-cadherin expression by RNA interference led to nuclear 
translocation of β-catenin and an enhancement of β-catenin/TCF-dependent 
reporter activity. On the other hand, forced expression of E-cadherin in L929 
fibroblasts which are deficient in both E-cadherin expression and Wnt signaling 
induces the stabilization of β-catenin at the cell junctions and resulted in evident 
changes in cell phenotype but no significant impact on the expression level of Wnt-
related genes. Recent study from Gottardi lab demonstrated that in S2480 colon 
carcinoma cell line, the forced expression of E-cadherin enhances the GSK-3β-
dependent phosphorylation of β-catenin N-terminus, leading to the inhibition of Wnt 
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signaling. This observation provides a novel mechanism underlying cadherin’s 
regulation on β-catenin activity (107).  
1.4.4. M-cadherin and its role in myogenesis and apoptosis. M-cadherin is a 
member of classic cadherins. It was first identified in differentiating muscle cells by 
Donalies and colleagues (108) in 1991. They reported that M-cadherin mRNA was 
present at low levels in myoblasts and up-regulated in myotube-forming cells but 
not detectable in mouse fibroblasts. Its gene locus is linked to the E-cadherin (but 
not N-cadherin) locus on chromosome 8 of mouse and the human homologue was 
mapped to chromosome 16q24.1 (109). During the process of myogenesis, M-
cadherin is specifically involved in secondary myogenesis and its expression is 
down-regulated after birth (110-112). In mature skeletal muscle, M-cadherin is only 
detectable on satellite cells and on the sarcolemma of myofibers underlying 
satellite cells. At early stages of regeneration, M-cadherin was exclusively and 
strongly expressed in myoblasts. After fusion of myoblasts into myotubes, M-
cadherin was down-regulated and was barely detectable on more mature 
myotubes surrounded by distinct basal lamina sheaths (113; 114). It’s reported that 
there was a significant decline in the number of M-cadherin-positive satellite cells 
in human muscle during aging (24).  
         During the past decade, the M-cadherin’s role in myoblast fusion has been 
established attributed to the studies from various groups. Kuch et al (115) reported 
that similar as E-cadherin and N-cadherin, M-cadherin formed two distinct 
cytoplasmic complexes in myogenic cells, either with α-catenin/β-catenin or with α-
catenin/plakoglobin, indicating that M-cadherin shares important features with the 
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classical cadherins in spite of its phylogenetic divergence. Zeschnigk and 
coworkers (116) treated myoblasts with antagonistic M-cadherin peptides and 
found the fusion of myoblasts into myotubes was inhibited and the expression of 
troponin T, an established marker of terminal myogenic differentiation, was 
downregulated. The cell cycle withdrawal process was also impaired. Their data 
strongly suggested that M-cadherin-mediated myoblast interaction plays an 
important role in terminal differentiation of skeletal muscle cells. Charrasse and 
coworkers demonstrated that M-cadherin may mediate myoblast fusion by 
activating Rac1 GTPase and its function is regulated by RhoA which promotes M-
cadherin’s degradation through lysosomal pathway (117; 118). In spite of the 
above evidences that establish M-cadherin’s role in myogenesis and muscle 
regeneration, there is another study questioning M-cadherin’s absolute necessity in 
myogenesis and muscle regeneration. Hollnel and colleagues generated an M-
cadherin-null mutation in mice. The mutant mice were viable and fertile and 
showed no gross developmental defects. The skeletal muscle appeared normal. 
Moreover, muscle lesions induced by cardiotoxin injection were efficiently repaired 
in mutant mice, suggesting that satellite cells can be activated to form new 
myofibers. Thus they concluded that M-cadherin in the mouse doesn’t serve 
absolutely required function during muscle development and regeneration and the 
lack of M-cadherin seems to be largely compensated by N-cadherin or other 
cadherins.  However, they failed to observe a compensatory increase in either the 
expression or the function of any other cadherins such as N-cadherin, in M-
cadherin-/- skeletal muscle. Furthermore, they didn’t demonstrate the status of 
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regeneration capability of muscle in aged M-cadherin-null mice (119). Thus the 
importance of M-cadherin in muscle regeneration, as well as the mechanism that 
how M-cadherin regulates muscle regeneration, remains to be elucidated. 
          Although the role of other cadherins, (e.g. E-cadherin, N-cadherin, VE-
cadherin), in regulating cell survival and death are under extensively investigation, 
there is no report published concerning M-cadherin’ role in regulating the apoptosis 
of myoblasts or satellite cells. Furthermore, the role of M-cadherin in regulating β-
catenin phosphorylation status and the impact of this regulation on canonical Wnt 
signaling and myogenesis has not been addressed yet. 
1.5. PI3K/Akt/GSK-3β pathway and its role in apoptosis and muscle 
remodeling 
1.5.1. PI3K/Akt pathway and its role in cell survival and apoptosis. 
Phosphatidylinositiol 3-kinase (PI3K) is a heterodimer composed of a regulatory 
subunit (p85) and a catalytic (p110) subunit and possesses activities of both 
phosphoinositide kinase and serine/threonine protein kinase (120; 121). P85 
subunit negatively regulates the catalytic activity of the p110 subunit (121). The 
trigger event for PI3K activation is the activation of receptor or non-receptor 
tyrosine kinases in response to ligation of growth factors on the plasma membrane, 
which leads to the autophosphorylation on tyrosine residues and 
transphosphorylation of adaptor proteins, generating specific phosphotyrosine 
sequences that bind to the SH2 domain of p85 and alleviates its inhibition on p110. 
This results in the enzymatic activation of PI3K (122). On the other hand, GTP-
associated Ras can induce the activation of PI3K by directly binding to the p110 
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subunit (123). Once activated, PI3K phosphorylates phosphatidylinositol at the 3’-
OH of the inositol ring and converts phosphatidylinositol (3,4,) biphosphate (PIP2) 
to phosphatidylinositol (3,4,5) triphosphate (PIP3) (124; 125). This functions as a 
lipid second messenger and has a high affinity to the pleckstrin (PH) domain-
containing proteins, including the serine/threonine kinase Akt. The binding to PIP3 
recruits Akt to the inner surface of plasma membrane (126). Phosphoinositide 
dependent kinase 1 (PDK1), another PH domain-containing protein, is also 
recruited to plasma membrane by PIP3 (127). Full activation of Akt requires 
phosphorylation of the Tyrosine308 and Serine473 residues by PDK1 and PDK2 
respectively (127-129). Akt is the key downstream target of PI3K that transmits 
most signals from PI3K. A large number of downstream effectors of Akt have been 
identified, including mTOR, p70S6K1, Forkhead (FH) transcription factors, GSK-
3β, IRS-1, caspase-9, Bad, and eNOS (130). The PI3K/Akt pathway has been 
established as one of the key signaling pathways that play a crucial role in 
regulating various cellular processes, such as cell proliferation, survival, 
differentiation, protein synthesis, glucose metabolism, and cell motility (129; 130). 
Akt is also known as protein kinase B (PKB). It was originally identified as the 
oncogene in the transforming retrovirus, AKT8, which was isolated from an AKR 
mouse thymoma cell line (131). AKT plays a crucial role in cellular survival 
pathways by phosphorylating a number of target proteins. Akt directly 
phosphorylates human procaspase-9 at serine196 and inhibits its protease activity 
(132). Akt also phosphorylates Bad, a proapoptotic member of Bcl-2 family, at the 
residue of serine136. This phosphorylation releases Bad from the complex with 
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Bcl-2/Bcl-XL localized on the mitochondrial membrane and promotes its binding to 
14-3-3 proteins in the cytosol, leading to the inhibition of its proapoptotic activity 
(133). In addition, Akt is able to phosphorylate Forkhead (FoxO) transcription 
factors and this phosphorylation leads to their nuclear exclusion and the 
suppression of FoxO-related proapoptotic transcription events (134-136). Akt also 
activates IKKα (IκB kinase α) and promotes NF-κB-mediated survival signaling 
(137). Furthermore, Akt phosphorylates Glycogen Synthase Kinase-3β (GSK-3β) 
at the N-terminal regulatory residue of serine 9, and this phosphorylation 
inactivates GSK-3β (138).  
1.5.2. GSK-3β: function, regulation, and its role in apoptosis. GSK-3β is a 
serine/threonine kinase that phosphorylates numerous substrates including 
transcription factors, structural proteins, and signaling proteins. It is involved in 
various physiological pathways such as glucose homeostasis and metabolism, cell 
cycle control, cell morphogenesis, development, tumor transformation, and 
neuroprotection. Thus it has been associated with many diseases including type II 
diabetes, inflammation, cancer, Alzheimer’s disease, and bipolar disorder (139; 
140). Since GSK-3β is constitutively active in cells under normal resting conditions, 
the primary regulatory mode of GSK-3β activity is to inactivate it, which is achieved 
by phosphorylation of an N-terminal residue of serine 9 which creates a 
pseudosubstrate that occupies the active site of the enzyme, preventing its 
interaction with real substrates (141). The kinases that are able to inactivate GSK-
3β include PKA (cyclic AMP-dependent protein kinase) (142), PKB/AKT (protein 
kinase B)(138), PKC (protein kinase C) (143), and p90RSK (p90 ribosomal S6 
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kinase) (144). In addition, there are more than 30 chemical compounds that has 
been identified to be the GSK-3 inhibitors (145). Lithium chloride (LiCl) is one of 
the earliest established inhibitor for GSK-3. LiCl inhibits GSK-3 activity by two 
mechanisms: firstly, it competes with ATP in the ATP-binding site of the kinase via 
directly competing with magnesium; secondly, it increases the inhibitory 
phosphorylation of Serine 9 residue of GSK-3β and Serine 21 residue of GSK-3α 
(146). The small heterocyclic thiadiazolidinones (TDZD) are the first group of 
chemicals that inhibit GSK-3β activity in a non-APT-competitive pattern (147). 
          GSK-3β is an established negative regulator of canonical Wnt signaling by 
phosphorylating β-catenin (39). GSK-3β also plays an important but paradoxical 
role in regulating apoptosis. Firstly, it promotes intrinsic mitochondria-associated 
apoptosis (148). GSK-3β can directly phosphorylate Bax at Serine163 which leads 
to Bax activation (149). GSK-3β promotes p53-induced intrinsic apoptosis by both 
upregulating its expression level and regulating its intracellular localization (150; 
151). GSK-3β can also phosphorylate and inhibit a number of transcription factors 
that favor the gene expression for anti-apoptotic proteins. For example, the β-
catenin/canonical Wnt signaling pathway has been shown to promote growth and 
survival. However, phosphorylation of β-catenin by GSK-3β results in its 
degradation and the turnoff of canonical Wnt signaling (39). Another survival-
promoting transcription factor that is inhibited by GSK-3β is HSF-1 (Heat shock 
factor-1), which induces the expression of several heat shock proteins that protects 
cells against apoptosis (152-154). Overexpression of GSK-3β has been shown to 
induce apoptosis in various types of cells, including PC12 cell and Rat1 fibroblasts 
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(155), cortical neurons (156), vascular smooth muscle cells (157), endothelial cells 
(158), and human umbilical vein endothelial cells (159). On the other hand, GSK-
3β antagonizes the death receptor-mediated extrinsic apoptosis (148). The mouse 
GSK-3β knockout model results in embryonic lethality because of massive liver 
apoptosis due to TNF hypersensitivity (160), indicating that GSK-3β inhibits TNF-
induced apoptosis. Although the exact molecular mechanism that underlies the 
anti-apoptotic effect of GSK-3β in extrinsic apoptosis remains to be elucidated, 
accumulating evidences suggest that GSK-3β-dependent anti-apoptotic effect is 
executed at a very early stage that precedes the initiating step of caspases-8 
activation (148).             
1.5.3. The role of GSK-3β in muscle wasting and satellite cell biology. Many 
studies have suggested that GSK-3β negatively regulates cardiac hypertrophy and 
inactivation of GSK-3β is an important mechanism in the development of cardiac 
hypertrophy (161; 162). In skeletal muscles, association between GSK-3β and 
various muscle wasting conditions has been reported in many studies. GSK-3β 
activity is increased in aged (163) and burn-injured skeletal muscles (164). The 
activity of GSK-3β is downregulated during myogenic differentiation induced by 
IGF-1 (165).  In addition, GSK-3β inhibition reduces protein degradation in wasting 
muscles and promotes re-growth of atrophic muscle (166-168). A conditional 
skeletal muscle knockout of GSK-3β shows an improved insulin tolerance and 
glucose metabolism in muscle tissues (169), but there is no data that evaluate a 
direct role of GSK-3β in regulating the muscle progenitor cell survival and 
apoptosis during myogenic differentiation.  
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         Regulation of GSK-3β activity has been shown to be a key event in mediating 
the switch between Notch and Wnt signaling as the muscle progenitor cells stop 
proliferation and start to commit to myogenic differentiation (49), suggesting that 
GSK-3β may play a crucial role in regulating the fate specification of satellite cells. 
 
1.6. Summary and relevance. 
          Number and functionality of satellite cells is crucial to adult muscle 
regeneration. Understanding the molecular mechanism that underlies the 
regulation of the survival and differentiation of satellite cells is critical to provide 
applicable information to potential clinical intervention of certain muscular 
dystrophic disorders. M-cadherin as a key component for cell-cell adhesions 
between myoblasts, its function in regulating the survival/apoptosis of myoblasts  
and the underlying pathways, as well as its role in regulating β-catenin/canonical 
Wnt signaling have not be addressed. In this dissertation, we tried to seek answers 
to the following questions: Does M-cadherin protects myoblasts against apoptosis 
or makes the myoblasts more susceptible to apoptosis, and what is the signaling 
pathway that mediates this effect? Does M-cadherin regulate phosphorylation 
status of β-catenin N-terminus in myoblasts? What is the impact of this regulation 
on canonical Wnt signaling and myoblast biological behavior? Our ultimate goal is 
to determine whether M-cadherin plays a critical role in regulating myoblasts 
biological behavior and fate specification and to get insights in novel molecular 
mechanism of muscle regeneration and to provide clues for novel therapeutic 
strategies for muscular dystrophic disorders.  
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                                                             ABSTRACT 
Apoptosis occurs concurrently with differentiation of muscle progenitor cells (MPCs) 
before they fuse to form myotubes. Dysregulated apoptosis in MPCs contributes to the 
low regeneration capability in aged muscle and decreases the survival rate of donor 
cells in stem cell-based therapies including muscular dystrophies. This study 
investigated the role of the M-cadherin/PI3K/Akt/GSK-3β signaling pathway in regulating 
apoptosis during differentiation of MPCs. Disruption of M-cadherin-dependent cell-cell 
adhesion by M-cadherin RNA interference (RNAi) in confluent C2C12 myoblasts 
sensitized the cells to mitochondria-associated intrinsic apoptosis induced by cell 
confluence or serum starvation. Further investigation of this pathway revealed that M-
cadherin-mediated signaling suppressed GSK-3β activation by enhancing the 
PI3K/AKT-dependent inhibitory phosphorylation of GSK-3βser9. Overexpression of wild-
type GSK-3β in confluent C2C12 myoblasts exacerbated the apoptosis, while chemical 
inhibition of GSK-3β (TDZD-8), or forced expression of constitutively active Akt 
(myrAkt), or a kinase-deficient GSK-3β (GSK-3βK85R) mutant, attenuated apoptosis 
and rescued the impaired myogenic differentiation that is caused by M-cadherin RNAi. 
These data suggest that M-cadherin-mediated signaling prevents acceleration of 
mitochondria-associated intrinsic apoptosis in MPCs via suppressing GSK-3β activation 
during myogenic differentiation.  
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                                                        INTRODUCTION 
Muscle progenitor cells (MPCs, i.e., satellite cells) remain quiescent both metabolically 
and mitotically in adult muscles under normal basal physiological conditions. Once 
activated by stimuli such as muscle injury or exercise, they enter the cell cycle, 
proliferate, differentiate, and fuse into myotubes for muscle regeneration (1; 2). The 
differentiation of MPCs is critical for myotube formation but it also occurs concurrently 
with apoptosis (3; 4). Apoptosis is a systematic process of programmed cell death which 
is important for normal tissue morphogenesis and development by maintaining the 
tissue homeostasis.  The dysregulation of apoptosis contributes to a variety of 
pathologies, including cancer, autoimmune diseases, cardiovascular disease and 
degenerative neurological diseases (5-7). In skeletal muscle, apoptosis has been linked 
to conditions of muscle wasting caused by disuse, denervation, and aging (8-10). In 
addition, inappropriate apoptosis of muscle progenitor cells may contribute to the low 
regeneration capability of dystrophic muscles and the poor outcomes of stem-cell-based 
therapeutic strategies (11-14). Decreased muscle progenitor cells number (15), function 
(16; 17), and altered responses to their niche (18; 19) contribute to the impaired 
regenerative capability in aging skeletal muscle. In addition, muscle progenitor cells that 
are isolated from aged muscle are susceptible to apoptosis and their number declines 
as more of them are depleted by apoptosis in aged muscle (20-22).  
 
M-cadherin is a member of the classical cadherin family of transmembrane 
glycoproteins mediating calcium-dependent homophilic cell-cell adhesion. M-cadherin is 
specifically expressed in skeletal muscle and certain neural tissues. In mature skeletal 
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muscle, M-cadherin is only detectable on satellite cells and the underlying sarcolemma 
of myofibers (23; 24). The number of M-cadherin-positive satellite cells decreases in 
aged muscle  (25). Although a mouse knockout model indicated that M-cadherin might 
play a dispensable role in myogenesis and muscle regeneration in vivo (26), data from 
in vitro studies showed that by interacting with Rac1 and other members of Rho 
subfamily, M-cadherin is critical in mediating myoblast alignment and fusion into 
myotubes (27-29). However, its role in regulating the survival and death of muscle 
progenitor cells/myoblasts has never been addressed.  
 
In the present study, we investigated the role of M-cadherin-dependent cell-cell 
adhesion on the survival of mouse C2C12 myoblasts as well as primary muscle 
progenitor cells during myogenic differentiation. We were particularly interested in the 
potential for M-cadherin to protect against the mitochondria-associated intrinsic 
apoptosis that is induced by cell confluence or serum starvation. By disrupting M-
cadherin-dependent cell-cell adhesion through knocking down M-cadherin expression 
via RNA interference, we demonstrated that M-cadherin-mediated signaling is important 
for maintaining mitochondrial integrity. This occurred by suppressing GSK-3β activation 
in a PI3K/Akt-dependent manner, and reducing apoptotic signaling through the 
mitochondrial pathway, thus promoting the survival of myoblasts during myogenic 
differentiation. Moreover, apoptosis and impaired myogenic differentiation that is caused 
by M-cadherin RNAi can be rescued by the inhibition of GSK-3β activation. Together, 
these results suggest an indispensable role of M-cadherin-mediated signaling in 
maintaining the balance between apoptosis and differentiation of muscle progenitor 
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cells during myogenesis and potentially during activation of muscle stem cells such as 
that occurring during muscle regeneration. 
                                              
                                         MATERIALS AND METHODS 
For detailed methods see Supplementary information. 
 
Cell Culture 
C2C12 myoblasts were purchased from American Type Culture Collection (Manassas, 
VA) and maintained in Dulbecco Modified Eagle’s Medium (DMEM) (Invitrogen Life 
Technologies, Bethesda, MD) supplemented with 10% fetal bovine serum (FBS) and 
1% antibiotic and antimycotic mixture solution (Invitrogen). Primary myoblasts were 
isolated from hindlimb muscles of one-week old C57BL/6 mice (30) and purified by 
Percoll (Sigma-Aldrich Co., St Louis, MO) gradient centrifugation. The Syndecan-4-
positive myoblasts were identified by fluorescence activated cell sorting (FACS) using a 
Syndecan-4 antibody (BD). The Syndecan-4-positive myoblasts were cultured in Ham’s 
F10 supplemented with 20% FBS at 37ºC. Serum starvation was induced by incubating 
the cells in serum-free DMEM supplemented with 1% antibiotic and antimycotics. 
Myogenic differentiation was induced by culturing the confluent cells in differentiation 
medium (DMEM, 2% horse serum, 1% antibiotic and antimycotic).  
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Chemical Inhibitors 
The cells were treated with a PI3K inhibitor Wortmannin (200 nM, Alexis Biochemicals, 
Plymouth Meeting, PA), a GSK-3 inhibitor, TDZD-8 (25 μM, Sigma), or a MEK1 inhibitor 
PD98059 (50 μM, Cell Signaling, Danvers, MA). 
 
Inhibition of M-cadherin expression by RNA interference 
The myoblasts were seeded at a density of 1.7 × 105 per well in a six-well plate, 24 
hours before transfection with SMARTpool small interfering RNA (siRNA) targeted to M-
cadherin mRNA (Life Thermo). The transfection media included either DharmaFECTTM-
3 reagent (Life Thermo) (for C2C12 myoblasts) or Lipofectamine 2000 (Invitrogen) (for 
primary myoblasts) at a final siRNA duplex concentration of 100nM. The efficacy of M-
cadherin protein knockdown by RNA interference (RNAi) was confirmed by 
immunoblotting. 
 
Plasmids and Transfection 
The full-length mouse wild-type GSK-3β cDNA was generated by RT-PCR. mRNA was 
derived from wild C2C12 myoblasts using Trizol reagent (Life Technologies, Inc.) and 
reverse-transcribed into cDNA using Superscript II (Life Technologies, Inc.). The PCR 
product was cloned into the expression vector pcDNA3.1/myc-His(-) (Invitrogen). The 
constitutively active mutant of Akt (myrAkt) and the V5-tagged kinase-deficient GSK-3β 
mutant (K85R) carried by vector pcDNA3 were generous gifts from Dr. Jia Luo. The 
cells were transfected with the wild-type GSK-3β plasmids using FuGENE 6 (Roche 
Diagnostics, Indianapolis, IN). The co-transfection of M-cadherin siRNA with myrAkt or 
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GSK-3β (K85R) plasmids was carried out using DharmaFECT Duo transfection reagent 
(Dharmacon, Inc., Thermo-Fisher Scientific, Lafayette CO).  
 
Recombinant M-cadherin-Fc treatment 
The recombinant M-cadherin-Fc chimera was purchased from R&D Systems 
(Minneapolis, MN). 6-well plates were pre-coated with goat anti-Fc antibody (0.5µg/cm2 
in PBS/Ca2+; Jackson ImmunoResearch, West Grove, PA) overnight at 4°C followed by 
coating with recombinant M-cadherin-Fc chimera at a final concentration of 2µg/cm2 in 
0.1%BSA/PBS/Ca2+ for 2 hours at room temperature. The dishes were blocked with 1% 
BSA/HBSS/Ca2. Plates coated with solely the anti-Fc antibody were used as vehicle 
controls.  The cells were seeded at 0.5 x 105 cells per well and grown for 48 hours 
before being harvested for further assays.  
 
Subcellular fractionation 
The membrane fraction of C2C12 myoblasts was prepared using a commercial reagent 
(Thermo Fisher). The nuclear protein fraction was prepared according to methods that 
have been previously described (31). The mitochondrial, mitochondria-free and nuclei-
free cytosolic fractions were prepared using mitochondria/cytosol reagents (BioVision, 
Mountain View, CA). The concentration of the protein extracts was quantified in 
duplicate by Bio-Rad DC Protein Assay (BioRad, Hercules, CA). The whole cell lysate 
was obtained by disrupting the cells with  RIPA buffer supplemented with protease and 
phosphatase inhibitor cocktails (Sigma-Aldrich, 1:100 dilution) followed by 
centrifugation. The supernatant was collected as the whole cell lysate.  
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Immunoblotting 
Antibodies specific to phosphoserine 473 Akt,  total Akt, phosphoserine 9 GSK3β, total 
GSK3β, cytochrome c, cleaved caspase-9 and cleaved caspase-3, AIF, survivin 
(1:1000) and cyclin D1 (1:2000 dilution) were purchased from Cell Signaling Technology 
(Danvers, MA). The anti-M-cadherin antibody (1:200) was obtained from Calbiochem 
(La Jolla, CA). The anti-caspase-8 antibody (1:250) was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Anti-histone H2B (1:5000), -β-tubulin (1:500) and -
GAPDH (1:5000) antibodies were obtained from Abcam (Cambridge, MA). The 
antibodies to manganese superoxide dismutase (MnSOD) and copper-zinc superoxide 
dismutase (Cu-ZnSOD) (1:1000) were purchased from Millipore (Billerica, MA). The 
secondary antibodies for immunoblotting including goat anti-rabbit or goat anti-mouse 
IgG conjugated with horseradish peroxidase (HRP) were obtained from Jackson 
ImmunoResearch Laboratories (West Grove, PA).  The proteins were separated on a 4-
12% gradient polyacrylamide gel (Invitrogen), and transferred to a nitrocellulose 
membrane (Bio-Rad, Hercules, CA). The membranes were probed with primary 
antibodies overnight at 4°C, followed by incubation of the appropriate secondary 
antibody for 1 hour at room temperature. The resulting signals were developed using an 
enhanced chemiluminescence lighting (ECL) Western blotting detection reagent kit (GE 
Health Care, Piscataway, NJ). Digital records were obtained from each blot and the 
protein bands of interest were quantified using 1-D analysis software (Eastman Kodak).  
The membranes were stripped and reprobed for β-tubulin, GAPDH, or Histone H2B as 
loading controls.  
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Immunoprecipitation 
The cells were washed in ice-cold PBS and lysed in ice-cold buffer (150 mM NaCl, 50 
mM Tris, pH 7.5, 0.25% SDS, 0.1% Nonidet P-40). Non-soluble materials were removed 
by centrifugation at 12,000 g.  The lysate was incubated with anti-PI3K-p85α (Abcam), 
anti-M-cadherin (Santa Cruz) or IgG (Millipore) overnight at 4°C. The sample was then 
incubated with Protein A/G PLUS-agarose beads (Santa Cruz) and the beads were then 
collected by centrifugation. The bound proteins were eluted from the agarose beads in 
Laemmli sample buffer (5X) at 95-100°C. The samples were clarified by centrifugation 
and the supernatants were separated by SDS-PAGE and immunoblotted against M-
cadherin or PI3K-p85α.  
 
Cell imaging 
Phase contrast images of live C2C12 and primary myoblast cells were obtained by a 
Nikon eclipse TS100 phase-contrast microscope. The digital images were obtained with 
a SPOT RT camera and analyzed with SPOT RT software (Diagnostic Instruments Inc., 
Sterling Heights, MI). Immunocytochemical assays were conducted on fixed cells after 
they had been grown coverslips. After fixation in 4% paraformaldehyde, the cells were 
incubated at 4°C with antibodies against anti-M-cadherin (1:20, Calbiochem) or anti-
myosin heavy chain (MyHC) (1:500, Developmental Studies Hybridoma Bank, Iowa 
City, IA). The cells were incubated with the Alexa Fluor 546 IgG (H+L) (Invitrogen) and 
counter-stained with 4,6-diamidino-2-phenylindole (DAPI). The cells were imaged with a 
Zeiss LSM510 confocal laser scanning microscope using AIM software (Carl Zeiss 
MicroImaging).  
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Myoblast fusion index. The myoblast fusion index was calculated as the ratio of the 
number of DAPI-positive nuclei located in the MyHC-positive myotubes (i.e., fused 
myoblasts) divided by the total number of nuclei in the same field. This fusion index was 
used as a read-out of myogenic differentiation. The fusion index was obtained from 10 
non-overlapping areas of each coverslip. 
 
Apoptosis assays 
DNA fragmentation. DNA fragmentation was used to assess the level of apoptosis in 
muscle cells using an ELISA (Roche) with measurements for DNA fragmentation that 
were made at an absorbance of 405nm (31; 32). The data were normalized to the 
protein concentration of the sample.  
 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). A TUNEL 
assay (Roche) was used to identify the extent of apoptotic nuclei in adherent myoblasts 
as reported previously (33). The nuclei of all cells were counter-stained with DAPI. The 
number of TUNEL- and DAPI-positive nuclei was counted in ten images from non-
overlapping areas of each group of cells. The data were presented as the apoptosis 
index, which was determined by the ratio of TUNEL-positive nuclei to the total number 
of DAPI-positive nuclei. To identify the full extent of apoptosis, and determine if M-
cadherin-RNAi treatment increased the sensitivity of C2C12 myoblasts to serum 
starvation-induced apoptosis, we assessed apoptosis by a TUNEL assay in both 
adherent and floating cells in each well using a published method (4).  The total percent 
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of apoptotic cells for each well was calculated as:  (the total number of TUNEL-positive 
attached cells + the total number of TUNEL-positive floating cells) /(total attached cells 
+ total floating cells).  
 
Cardiolipin content and mitochondrial membrane potential measurement 
Nonyl acridine orange (NAO, Invitrogen) was used to determine the cardiolipin content 
in the inner mitochondrial membrane as an indicator of mitochondrial integrity. C2C12 
myoblasts were transfected with M-cadherin-targeted (M-) or scrambled siRNA (siCON) 
with NAO (250nM) at 37ºC. Fluorescence was visualized with a Nikon eclipse E800 
fluorescence microscope and digital images were captured using a SPOT RT camera 
(Diagnostic Instruments, Inc). The fluorescence intensity was analyzed and quantified 
using the ImageJ software (NIH). 
 
To measure changes in the mitochondrial membrane potential, mitochondria were 
isolated from M-cadherin RNAi or control cells. The purity of mitochondria was verified 
by staining with MitoTracker Deep Red 633 (Molecular Probes, Carlsbad, CA), a 
mitochondria-specific marker and analyzed by flow cytometry. This fluorescent dye 
diffuses passively into intact and respiring mitochondria. The mitochondrial membrane 
potential (Δψmt) was estimated by staining the mitochondria with 5,5',6,6'-tetrachloro-
1,1',3,3'-tetraethylbenzimidazolyl carbocyanine iodide (JC-1) (Molecular Probes). The 
staining results of JC-1 orange/green were analyzed using a FACSCalibur system (BD 
Bioscience) using Cell Quest Pro. 4.0 Software. 100,000 gated events were collected 
for each sample. 
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Statistical analyses 
The results are presented as mean ± standard error of mean (SE). Statistical analyses 
were performed using the SPSS 13.0 software package. A one-way analysis of variance 
(ANOVA) was used to compare differences in all measured variables. P < 0.05 was 
considered statistical significant. 
 
                                                             RESULTS 
M-cadherin RNA interference exacerbates mitochondria-associated apoptosis in 
confluent C2C12 myoblasts.  To evaluate the apoptotic propensity to low and high cell 
densities, C2C12 myoblasts were seeded in 6-well plates at either 2.0 x103/cm2 to 
obtain a low density (~ 20-30% confluent) or 2.1x104/cm2 to reach a high cell density 
(~100% confluent) within 48 hours. The phase-contrast images in the top panel of 
Figure 4A show typical morphology of C2C12 myoblasts at low or high cell densities.  
The middle panel of Figure 4A shows that the protein abundance of cleaved caspase-3 
and Poly (ADP-ribose) polymerase (PARP) was markedly increased in fully confluent 
cells as compared with cells that were plated at a low density. The cleavage of PARP by 
caspases leads to nuclear DNA fragmentation. Furthermore, a cell death ELISA assay 
showed an elevation of cytosolic nucleosomes at full cell confluence (bottom panel, 
Figure 4A). This provided additional evidence for an increase in apoptotic DNA 
fragmentation in confluent cells compared with non-confluent cells. We next explored 
the expression pattern and level of M-cadherin at different cell densities. As shown in 
the top panel of Figure 4B, M-cadherin was located diffusely throughout the cells that 
were plated at a low density. In contrast, M-cadherin relocated to cell-cell contacts at 
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the periphery of the cells when they were confluent. The protein abundance of M-
cadherin increased in confluent C2C12 myoblasts compared with the non-confluent 
cells (bottom panel, Figure 4B). To investigate the role of M-cadherin in regulating 
myoblast survival and apoptosis, we inhibited M-cadherin expression in confluent 
C2C12 myoblasts via transient transfection with M-cadherin-targeted small interfering 
RNA (siRNA). Figure 4C shows that the knockdown of M-cadherin expression in 
confluent C2C12 myoblasts causes a disruption in the cell-cell contacts and this 
increased the separation between the cells. Cells in the control group adhered tightly to 
each other as the cells became confluent (Figure 4C). The knockdown of M-cadherin 
was verified by immunoblotting (Figure 4D). In control groups, the M-cadherin signals 
were detected in a multi-band pattern because most cadherins undergo various 
posttranslational modifications and truncation to get to their mature form (34). The 
protein abundance of N-cadherin in C2C12 cells was not affected by M-cadherin RNAi 
treatment (Figure 4D). M-cadherin RNAi exacerbated cell confluence-induced apoptosis 
in C2C12 cells as determined by the increased protein abundance of cleaved caspase-3 
and cleaved PARP (Figure 4D). An increase in DNA fragmentation as measured by a 
cell death ELISA assay (Figure 4E) confirmed that M-cadherin RNAi increased the level 
of cell confluence-induced apoptosis.  
 
Apoptosis is initiated in muscle by three pathways. These include the extrinsic death 
receptor-mediated, the intrinsic mitochondrial-dysfunction associated and the intrinsic 
endoplasmic reticulum-dysfunction associated pathways (10; 35; 36). To further clarify 
which apoptotic pathway was most likely involved in cell death caused by M-cadherin 
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RNAi, we examined the activation status of caspase-9 and caspase-8, which are 
representative initiation caspases for the intrinsic or the extrinsic apoptotic pathway, 
respectively. The protein abundance of cleaved caspase-9 but not caspase-8 was 
markedly increased in response to M-cadherin RNAi (Figure 4F). In addition, the protein 
abundance of cytosolic cytochrome c and nuclear apoptosis inducing factor (AIF) were 
also increased upon M-cadherin RNAi. This suggests that the apoptosis that was 
induced by M-cadherin RNAi was mediated via the intrinsic mitochondria-associated 
pathway. To further investigate the impact of M-cadherin RNAi on mitochondria as a 
mediator of apoptosis, we examined the cardiolipin content of the inner mitochondrial 
membrane of live cells using nonyl acridine orange (NAO) staining. NAO is a 
metachromatic dye that binds specifically to the mitochondrial cardiolipin and its 
fluorescence intensity is an indicator of mitochondrial integrity (37; 38). The median 
fluorescence intensity of NAO staining in M-cadherin-RNAi treated cells was 
significantly lower than that in control cells (Figure 4G). This indicates that the integrity 
of mitochondria in C2C12 cells was disrupted after M-cadherin RNAi treatment. 
Furthermore, the mitochondria membrane potential (Δψmt) was also disrupted by 
reducing M-cadherin in confluent cells, as shown by a decrease in the orange/green 
signals from M-cadherin RNAi treated mitochondria compared with the control 
mitochondria after incubation with the fluorescent probe JC-1 (Figure 4H). JC-1 is a 
mitochondria permeable lipophilic cation that changes its color from orange to green as 
the Δψmt decreases. A reduced Δψmt leads to a shift of the emitted light from 590nm 
(orange) to 530nm (green) (39).   
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M-cadherin RNAi sensitizes C2C12 myoblasts to serum-starvation-induced 
apoptosis. To further explore M-cadherin’s role in regulating mitochondrial integrity and 
cell survival/apoptosis during myogenic differentiation, M-cadherin-RNAi-treated or 
control C2C12 myoblasts were cultured in serum-free medium. Mitochondria were 
isolated and Δψmt was assessed by JC-1 staining after 0, 6, 12, 24 or 48 hr of serum 
starvation. There was a transient decrease in the ratio of JC-1 orange/green staining of 
isolated mitochondria from all groups of cells in response to serum starvation, but the 
M-cadherin-RNAi-treated group had the lowest Δψmt at all time points compared with 
the control cells (Figure 5A). These results show that knocking down M-cadherin by 
RNAi reduced Δψmt during serum starvation. The level of apoptotic DNA fragmentation 
was significantly increased in M-cadherin RNAi-treated cells that were still attached to 
the plates at all time points of serum starvation compared with the control groups 
(Figure  5B). Furthermore, quantification of apoptotic cells from both attached and 
floating cell populations by TUNEL staining, demonstrated that there was a significant 
increase in the number of cells undergoing apoptosis during serum starvation in M-
cadherin RNAi-treated cells as compared with the control groups (Figure 5C). In 
addition, there are fewer cells that remained attached to the plates in the M-cadherin 
RNAi-treated group as compared with control groups when serum starvation progressed 
to longer time periods (Figure 12). Serum starvation caused an acute activation of 
cleaved caspase-9 in C2C12 myoblasts, which is indicative of activation of the 
mitochondrial-associated apoptotic pathway. The protein abundance of cleaved 
caspase-9 was significantly higher in M-cadherin RNAi treated cells at all time points of 
serum starvation as compared with control cells (Figure 13). This suggests that 
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knockdown of M-cadherin expression sensitizes C2C12 myoblasts to serum-starvation-
induced apoptosis. 
 
M-cadherin-mediated signaling enhances PI3K/Akt-dependent inhibitory 
phosphorylation of GSK-3βser9.  Akt is a key mediator of survival signaling pathways, 
and it is associated with cadherin signaling in various cells (40; 41). Since GSK-3β, 
another key regulator of cell fate and a phosphorylation target of Akt, is associated with 
muscle wasting, we also examined the change in GSK-3β phosphorylation in response 
to M-cadherin RNAi treatment in confluent cells. As a functional read-out for GSK-3β 
activation, the protein abundance of two targets for GSK-3β, cyclin D1 (42) and survivin 
(43) were measured. M-cadherin RNAi significantly reduced the activation of Akt in 
confluent C2C12 cells as determined by the expression of phospho-Aktser473 (Figure 
6A). Consequently, the inhibitory phosphorylation of GSK-3βser9 was decreased in cells 
that were treated with M-cadherin RNAi. Quantification of the immunoblot signals from 
four independent experiments showed a statistically significant and a reproducible 
(bottom panel of Figure 6A and Figure 15A-D) reduction in phospho-Aktser473, GSK-3β 
phosphorylation, survivin and cyclin D1 in C2C12 cells after M-cadherin RNAi treatment. 
Conversely, the activation of M-cadherin-mediated signaling via a recombinant M-
cadherin-Fc chimera treatment induced a significant increase in phosphorylation of Akt 
and GSK-3β at the corresponding residues (Figure 6B and Figure 16A, 16B). The 
protein abundance of survivin and cyclin D1, were increased in response to 
recombinant M-cadherin-Fc chimera treatment (Figure 6B; Figure 16C, 16D). 
Immunoprecipitation data show that the binding between the p85α subunit of PI3K and 
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M-cadherin was increased in response to recombinant M-cadherin-Fc chimera 
treatment (Figure 6C).  The protein abundance of PI3K-p85α in the membrane fraction 
was markedly increased in M-cadherin-Fc-treated cells compared with the control cells 
(Figure 6D). Treatment with the PI3K inhibitor, Wortmannin, but not the MEK-1 inhibitor, 
PD9805, during the last 6 hours of M-cadherin-Fc treatment, completely prevented the 
increase in phospho-Aktser473 and phospho-GSK-3βser9. This shows that the increased 
inhibitory phosphorylation of GSK-3β that is induced by M-cadherin-mediated signaling, 
is PI3K dependent (Figure 6E).  
 
GSK-3β overexpression exacerbates, whereas M-cadherin-Fc treatment 
attenuates apoptosis induced by cell confluence or serum starvation. To further 
characterize the role of GSK-3β in regulating apoptosis, C2C12 myoblasts that were 
80% confluent were transiently transfected with a wild-type GSK-3β plasmid and 
allowed to grow for 48 hours until they reached overconfluence. The transfection 
efficiency of the GSK-3β plasmid by FuGENE 6 in C2C12 cells was estimated to be 
~20-30% (Figure 14A).  Immunoblot analysis confirmed that transfection with GSK-3β 
increased the protein abundance of GSK-3β and decreased the protein level of cyclin 
D1 (Figure 7A), a target of GSK-3β phosphorylation that induces its degradation. 
Overexpression of wild-type GSK-3β in confluent C2C12 myoblasts increased the 
protein abundance of cleaved caspase-9, caspase-3, and PARP. This effect was 
reversed by co-treating the cells with recombinant M-cadherin-Fc (Figure 7B and 7C). In 
addition, Δψmt was decreased in mitochondria from C2C12 cells upon overexpression of 
wild-type GSK-3β, which was rescued by recombinant M-cadherin-Fc co-treatment 
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(Figure 7D). Together these data indicate that overexpression of wild-type GSK-3β 
alone is sufficient to exacerbate the mitochondria-associated apoptosis induced by cell 
confluence and this effect can be reversed by enhancement of M-cadherin-mediated 
signaling via M-cadherin-Fc treatment. Furthermore, in response to serum starvation, 
the wild-type GSK-3β plasmid-transfected cells had significantly higher cell death than 
the control cells at all time points, suggesting that overexpression of wild-type GSK-3β 
sensitized the cells to serum starvation-induced apoptosis (Figure 7E).  In contrast, co-
treatment of C2C12 cells with M-cadherin-Fc and wild-type GSK-3β overexpression 
after 48 hours of serum starvation significantly attenuated  cell death, as compared to 
GSK-3β overexpression alone (Figure 7F). 
 
GSK-3β inhibition attenuates the apoptosis exacerbated by M-cadherin RNAi. The 
role of GSK-3β inhibition on M-cadherin’s role in regulating apoptosis was examined 
using a myristoylated Akt mutant (myrAkt) which functions as a constitutively active form 
of Akt (44), to inhibit GSK-3β activity, and a V5-tagged kinase-deficient mutant GSK-
3β(K85R), which functions as a dominant negative GSK-3β (45). The transfection 
efficiency of these plasmids using DharmaFECT Duo in C2C12 myoblasts was 
estimated to be 25-35% as determined from transfecting studies using the pEGFP-C3 
vector and DharmaFECT DUO as the transfection agent (Figure 14B).  
To evaluate the effects of GSK-3β inhibition on apoptotic signaling, C2C12 cells that 
were 80% confluent were transfected with M-cadherin-targeted siRNA, plus either the 
myrAkt or the GSK-3β(K85R) plasmid, or an empty vector. The cells were allowed to 
grow for 48 hours at which time they had reached overconfluency. As expected, there 
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was a significant increase in both phospho-Akt and total-Akt abundance in the cells 
transfected with the myrAkt plasmid (Figure 8A, right panel). In addition, there was an 
increase in total GSK-3β and cyclin D1 protein abundance in the cells that were 
transfected with GSK-3βK85R plasmids (Figure 8A, left panel). Forced expression of 
myrAkt or GSK-3βK85R plasmids significantly attenuated apoptosis as seen by lower 
levels of cleaved-caspase-9, cleaved-caspase-3, and cleaved-PARP (Figure 8B and 
8C) after M-cadherin RNAi treatment or overconfluency. Furthermore, co-transfection of 
myrAkt or GSK-3βK85R plasmid with M-cadherin-targeted siRNA significantly reduced 
DNA fragmentation that was caused by 48-hours serum starvation alone or exacerbated 
by M-cadherin RNAi treatment (Figure 9A). To further confirm the impact of GSK-3β 
inhibition on M-cadherin’s regulatory effect on apoptosis, we transfected the cells with 
M-cadherin-targeted siRNA for 36 hours followed by treatment with TDZD-8 (20µM) for 
12 hours. TDZD-8 is an established non-ATP competitive inhibitor for GSK-3β (46). 
TDZD-8 treatment abrogated apoptosis and reversed the loss of Δψmt that was caused 
by M-cadherin RNAi following a period of 48-hours of serum starvation (Figure 9B, 9C).  
 
GSK-3β inhibition partially restores the myogenic differentiation impaired by M-
cadherin RNAi. Lastly, we sought to investigate the impact of M-cadherin RNAi and 
GSK-3β inhibition on the outcome of myogenic differentiation. M-cadherin-RNAi C2C12 
myoblasts treated with or without TDZD-8 were cultured in differentiation medium for 48 
hours to induce myogenic differentiation. Immunofluorescent staining of myosin heavy 
chain (MyHC) was used as a terminal myogenic marker. A TUNEL assay was 
performed to determine the level of in situ apoptotic DNA fragmentation.  Knockdown of 
66 
 
M-cadherin by RNAi significantly impaired myogenic differentiation, as many cells died 
and detached from the plates. In contrast, TDZD-8 treatment partially restored the 
myogenic differentiation that was blocked by M-cadherin RNAi. This was determined by 
the myoblast fusion index, which represented the percentage of myoblasts that matured 
into myotubes (Figure 10A, 10B). Calculation of the apoptotic index from TUNEL 
labeling showed that TDZD-8 treatment significantly attenuated the number of apoptotic 
nuclei that was caused by M-cadherin RNAi over 48-hours of myogenic differentiation 
(Figure 10A, 10C).  
 
These findings were further verified in mouse primary myoblasts. Syndecan-4-positive 
primary myoblasts were isolated by fluorescence activated cell sorting (FACS) as 
representative muscle progenitor cells (18; 47). ~20% of the adult muscle stem cells 
were Syndecan-4 positive (Figure 11A). Knockdown of M-cadherin by RNAi significantly 
impaired myotube formation from Syndecan-4-positive primary myoblasts, which was 
partially rescued by TDZD-8 treatment as shown from MyHC staining and a greater 
fusion index (Figure 11B and 11C) in the TDZD-8 treated cells.  Furthermore, M-
cadherin RNAi exacerbated apoptosis in Syndecan-4-positive primary myoblasts after 
48-hours of myogenic differentiation. Apoptosis could be abrogated by TDZD-8 
treatment, as shown by a lower TUNEL staining (Figure 11B) and an apoptotic index 
(Figure 11D) after TDZD-8 treatment. 
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                                                           DISCUSSION 
This is the first report to show that M-cadherin-mediated signaling protects myoblasts 
against apoptosis during myogenic differentiation.  In vitro culture of myoblasts at high 
cell density has been shown to yield not only a better myogenic differentiation outcome, 
but also an increased incidence of apoptosis, as compared to culturing the cells at a low 
density (4). This observation is consistent with the suggestion that apoptosis and 
differentiation are tightly regulated in a coordinate pattern in myoblasts (3). In the 
current study we show that M-cadherin protein abundance is increased and M-cadherin 
engagement at cell-cell contacts is induced when myoblasts become confluent. While 
confluence triggers apoptosis during differentiation, other cells survive, differentiate and 
fuse into myotubes (3; 4; 48-50). 
 
In this study we show that the disruption of M-cadherin signaling by M-cadherin RNAi, 
sensitized C2C12 myoblasts to apoptosis that was induced by either cell confluence or 
serum starvation. Apoptosis in C2C12 cells is accompanied by decreased Δψmt, 
increased mitochondrial release of cytochrome c and AIF, and consequently an 
increased cleavage of caspase-9 but not caspase-8. Together these data indicate M-
cadherin RNAi–induced apoptosis is mediated by the intrinsic mitochondria-associated 
pathway and M-cadherin-mediated signaling plays an important role in maintaining the 
mitochondrial integrity of differentiating myoblasts and suppressing apoptosis during 
myogenic differentiation. Our findings are consistent with data showing that Δψmt is 
compromised in myoblasts undergoing apoptosis but not those that successfully 
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differentiate (51). Furthermore, proper mitochondria function is critical for successful 
myogenic differentiation (37; 52; 53). 
 
Previous findings have shown that in aged muscle, the number of M-cadherin-positive 
satellite cells is decreased (25) but the apoptotic propensity of satellite cells is increased 
compared with those in young animals (20; 21). This suggests that there may be a 
negative relationship between the expression level of M-cadherin and the apoptosis 
susceptibility of muscle progenitor cells. In the current study, we show that M-cadherin 
has a protective role against apoptosis during myogenic differentiation since inhibition of 
M-cadherin expression by RNAi, sensitized both C2C12 and Syndecan-4-positive 
primary myoblasts to apoptosis, which resulted in an increase in pro-apoptotic markers, 
and resulted in an impaired myotube formation as compared to control cells. We 
speculate that reduced M-cadherin might be a contributing mechanism that would 
explain, at least in part, an increased susceptibility of muscle progenitor cells to 
increased apoptotic signaling and elimination of nuclei in aged muscles (10; 20; 21; 36).  
 
GSK-3β is a serine/threonine kinase that is constitutively active in resting cells and 
plays a key role in regulating glucose homeostasis (54). GSK-3β is also important in 
regulating apoptosis. However, it has a paradoxical effect on apoptosis from different 
pathways by promoting mitochondrial-dysfunction-associated apoptosis signaling, but 
also inhibiting death-receptor-mediated apoptosis signaling (55). Dysregulation of GSK-
3β has been reported to be involved in several pathologies including neurodegenerative 
diseases, mood disorders, cancer, and diabetes  (55). Studies in skeletal muscles have 
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linked GSK-3β to muscle wasting conditions. GSK-3β activity has been shown to 
increase in aged (56) and burn-injured skeletal muscles (57). Inhibition of GSK-3β is 
required for IGF-1-induced myogenic differentiation (58).  Furthermore, GSK-3β 
inhibition reduces protein degradation in conditions of muscle wasting and may also 
promote re-growth of atrophic muscle (59-61). Although a conditional skeletal muscle 
knockout of GSK-3β has been reported to manifest a phenotype with an improved 
insulin tolerance and glucose metabolism in muscle tissues (62), currently, there are no 
data that evaluate a direct role of GSK-3β in regulating the muscle progenitor cell 
survival and apoptosis during myogenic differentiation. In this study we show for the first 
time that overexpression of wild-type GSK-3β is sufficient to induce apoptosis in 
confluent C2C12 myoblasts and to sensitize the cells to serum-starvation-induced 
apoptosis. This effect can be attenuated by increasing M-cadherin-mediated signaling 
via recombinant M-cadherin-Fc treatment. We also show that the activation of M-
cadherin-mediated signaling recruits PI3K and activates Akt, which in turn 
phosphorylates GSK-3β at the serine 9 residue, resulting in its suppression. Conversely, 
inhibition of GSK-3β activation attenuates apoptosis that is induced by knockdown of M-
cadherin expression. This suggests that GSK-3β plays a critical role in mediating M-
cadherin’s protective effect against apoptosis during myogenic differentiation. Our 
findings are consistent with data from Robakis and colleagues (63) who showed that the 
expression of presenilin-1 in fibroblasts promotes the association of PI3K with E- and N-
cadherins and activates Akt, leading to the inhibition of GSK-3β activity. Skeletal muscle 
is the largest consumer of glucose and GSK-3β plays an important role in regulating 
glucose metabolism and insulin sensitivity in muscle (62; 64). Thus we speculate that 
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manipulation of M-cadherin-mediated cell-cell adhesion may have a profound impact on 
glucose metabolism and insulin tolerance of muscle tissue through regulating the 
activation status of GSK-3β. Interestingly,  a type 2 diabetic phenotypic KK/Ta mouse, 
has been shown to have an ectopic expression of M-cadherin in liver with three 
missense mutations (65). Further statistical analysis revealed a correlation between M-
cadherin expression and the hypertriglyceridemia, glucose intolerance and 
hyperinsulinemia in the KK/Ta mouse. This suggests that disrupted M-cadherin 
signaling may have a role in the pathology of type 2 diabetes (65).  
 
GSK-3β may regulate mitochondrial outer membrane permeabilization by targeting 
multiple substrates. The Bcl-2 family of proteins represents one target of GSK-3β. GSK-
3β directly phosphorylates the pro-apoptotic Bax protein at serine 163, leading to its 
activation (66). GSK-3β activation also induces the expression of the pro-apoptotic Bim 
protein (67). On the other hand, GSK-3β phosphorylation of MCL-1, an anti-apoptotic 
member of Bcl-2 family protein, facilitates its degradation (68). Another class of GSK-3β 
substrates in regulating apoptosis is a group of transcription factors that include p53, β-
catenin, and Myc. p53 plays a crucial role in regulating cell cycle arrest, senescence 
and apoptosis. GSK-3β can form a complex with nuclear p53 and this promotes p53-
induced apoptosis (69). β-catenin is a key mediator for the canonical Wnt signaling 
pathway, which plays an important role in promoting cell growth and survival. β-catenin 
also connects cadherins to the actin cytoskeleton. Together with adenomatous 
polyposis coli (APC) and axin, GSK-3β forms the “destruction complex” that 
phosphorylates β-catenin and promotes its ubiquitination and degradation (70). 
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Cadherins control both the turnover rate and the subcellular distribution of β-catenin. As 
a result, β-catenin could be the nexus for the convergence of cadherin and GSK-3β-
mediated signaling in skeletal muscle.  Additional studies are required to identify the 
important upstream mediators and downstream targets for M-cadherin/Akt/GSK-3β 
signaling that are responsible for maintaining mitochondrial integrity and suppressing 
apoptosis in myoblasts; however, this is beyond the scope of the current investigation.  
 
In conclusion, the data in the current study show that M-cadherin plays a critical role in 
regulating survival versus death via apoptosis of myoblasts during myogenic 
differentiation in vitro. M-cadherin-mediated signaling maintains the inhibitory tone from 
PI3K/Akt upon GSK-3β by activating PI3K/Akt. M-cadherin signaling appears to help 
maintain a balance between apoptosis and differentiation and prevents the acceleration 
of mitochondrial-associated apoptotic signaling in muscle cells.  
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Figure 4. Effect of M-cadherin RNAi on apoptosis in confluent C2C12 myoblasts.  
A. Top panel: Representative phase-contrast images of C2C12 myoblasts that were 
obtained 48 hours after seeding them at a low density (2.0 x103/cm2), or a high density 
(2.1x104/cm2). The objective magnification = 10x. The scale bar = 200 μm. Middle 
panel: Immunoblots of cleaved caspase-3 and PARP obtained 48 hr post plating. 
Bottom panel: Cytosolic nucleosomes of low or high-density cells were measured an 
indication of apoptotic DNA fragmentation. Each data point represents the mean ± SEM 
of the mean of three independent experiments. *, P<0.05 vs. the low-density group.  
B. The expression pattern and protein abundance of M-cadherin at low and high cell 
densities. Top panel: Representative confocal images of M-cadherin (red) and DAPI 
(blue) staining in C2C12 myoblasts at low or high cell density as described in Figure 1A.  
The objective magnification = 63x. The scale bar = 10 μm. Bottom panel: 
Immunoblotting analysis of protein abundance of M- cadherin. β-tubulin was probed as 
a loading control.  
 C-H, 80% confluent C2C12 myoblasts were transfected with M-cadherin-targeted siRNA 
(M-) or non-targeted scramble siRNA (SiCON) as a control. Non-transfected cells with 
identical culture conditions were used as a normal control (NC) cells. The cells were 
harvested 48hr post-transfection. Each data point (mean ± SEM) is the mean of three 
independent experiments. * , P<0.05 vs. the control groups.  
C. Phase-contrast images of transfected cells that were acquired at an objective 
magnification = 20x. The scale bar = 100.  
D. Immunoblot analysis of transfected cells.  
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E. The apoptotic DNA fragmentation of transfected cells is shown as mean± SEM of 
three independent experiments. *, P<0.05 vs. both NC and SiCON control groups.  
F.  Left panel: Proteins associated with apoptotic signaling (and the relevant control 
proteins) were measured in transfected and control cells. Right panel:  The integrity and 
purity of protein subcellular fractions was verified by immunoblotting with appropriate 
control antibodies.   
G. TOP panel: Digital images were obtained (objective=100x; scale bar = 20 μm) from 
control or transfected C2C12 cells that were stained with NAO. Bottom panel: The 
median fluorescence intensity of NAO per cell was determined. The data are mean± 
SEM of three experiments.  
H. Mitochondria were isolated from control and transfected cells and stained with JC-1. 
The data represent FACS analyses of the ratio of orange (intact mitochondria) to green 
(compromised Δψm) mitochondria.  
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Figure 5. Effect of M-cadherin RNAi on serum starvation-induced apoptosis. M-
cadherin-RNAi (M-), non-targeted scrambled siRNA-transfected (SiCON) or normal 
control (NC) C2C12 myoblasts were serum starved from zero to 48 hours before being 
harvested. *, P<0.05 vs. both SiCON and NC control groups. The data are shown as the 
mean± SEM for three independent experiments.  
A. Mitochondria were isolated from attached cells after serum starvation for 0 hours 
(SS-0h), 6 hours (SS-6h), 12 hours (SS-12h), 24 hours (SS-24h) or 48 hours (SS-48h). 
The mitochondria Δψm (orange/green ratio) was evaluated by FACS analysis JC-1 
staining.  
B. DNA fragmentation in attached cells was measured by a cell death ELISA at the 
same time points as described in A.   
C. The percentage of cells undergoing apoptosis in both attached and floating cells 
were defined as: total TUNEL-positive attached cells + total TUNEL-positive floating 
cells) divided by (total attached cells + total floating cells.  
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Figure 6. M-cadherin-mediated signaling effect on the PI3K/Akt/GSK-3β pathway.  
A-E. The data are shown as the mean± SEM for three independent experiments.    
A-B *, P<0.05 vs. the control groups. 
A. Top panel: Representative immunoblots of M-cadherin-RNAi (M-) treated, non-
targeted scrambled siRNA-transfected (SiCON) treated or normal control (NC) C2C12 
cells. Survivin and cyclin D1 were measured as a functional read-out for GSK-3β 
activation. GAPDH was used as a loading control. Bottom Panel: Densitometric 
analyses of Akt, GSK-3β, survivin and cyclin D1 normalized to their loading controls.  
B. Top panel: C2C12 myoblasts were grown in normal control (NC), vehicle control 
(Vehicle) or recombinant M-cadherin-Fc-coated (M-cad-Fc) dishes for 48 hours. The 
cells were lysed and subjected to immunoblotting analysis of the same proteins as 
measured in Fig. 3A. Bottom Panel: Densitometric analyses of immunoblot band 
intensities of phosphorylated and total Akt and GSK-3β, as well as survivin and cyclin 
D1 in response to recombinant M-cadherin-Fc treatment. The band intensities of the 
above proteins were normalized by corresponding control proteins.  
C. Immunoprecipitation assays of untreated C2C12 myoblasts (NC) or myoblasts 
treated with either the vehicle (Veh) or with recombinant M-cadherin-Fc (rMFc) were 
conducted 48 hr after treatment with either a mouse anti-PI3K-p85α or a rabbit anti-M-
cadherin antibody respectively. Western blots of the protein abundance of M-cadherin 
or PI3K-p85α were conducted in the precipitated proteins.  
D. Cell membrane fractions were prepared from cells that had been treated as 
described in Fig. 3C and blotted to detect the protein abundance of PI3K-p85α. 
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E. C2C12 myoblasts were treated as described in Fig. 3C. The cells were then treated 
for a subsequent 12 hours with no vehicle added (-), Wortmannin (WM, 200nM), 
PD98059 (PD, 50µM), Wormannin plus PD98059 (WM+PD), or DMSO.  Untreated 
normal control cells (NC) did not receive either the recombinant M-cadherin-Fc or the 
vehicle treatments. The cells were harvested for immunoblotting analysis.  
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Figure 7. Effect of wild-type GSK-3β overexpression and recombinant M-cadherin-
Fc treatment on apoptosis that was induced by cell confluence or serum 
starvation.  
A. A wild-type GSK-3β plasmid (GSK-3βWT) or an empty vector (EV) were transiently 
transfected into C2C12 myoblasts that were 80% confluent. 48 hours after transfection, 
the cells were harvested in RIPA buffer and processed for immunoblotting for GSK-3β 
and cyclin D1 protein abundance. The experiment was repeated three times under each 
experimental condition. 
B. Wild-type GSK-3β plasmids (GSK-3βWT) or empty vectors (EV) were transiently 
transfected into C2C12 myoblasts growing in recombinant M-cadherin-Fc-coated (M-
cad-Fc) or vehicle-coated (Vehicle) dishes. 48 hours later, the cells were harvested in 
RIPA buffer and immunoblotted against pro-apoptotic proteins.  GAPDH was probed as 
a loading control.  
C. Analyses of immunoblot bands described in 4B. The data were normalized to 
GAPDH and expressed as the mean ± SEM from three independent experiments.         
*, P<0.05 vs. EV/Vehicle or EV/M-cad-Fc; †, P<0.05 vs. GSK-3βWT/Vehicle.  
D. Mitochondria were isolated from C2C12 myoblasts that had undergone the same 
treatments as described in Fig. 4B. The mitochondria were stained with JC-1. A 
FACSCalibur system was used to measure the change in mitochondrial membrane 
potential (Δψm). The data are expressed as the ratio of orange/green JC-1 staining. The 
data are reported as the mean ± SEM from three independent experiments.  *, P<0.05 
vs. EV/Vehicle or EV/M-cad-Fc; †, P<0.05 vs. GSK-3βWT/Vehicle.  
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E. C2C12 myoblasts transfected with the wild-type-GSK-3β plasmid (GSK3βWT) or the 
empty vector (EV) and the non-transfected normal control (NC) cells were serum-
starved for 0 hours (SS-0h), 6 hours (SS-6h), 12 hours (SS-12h), 24 hours (SS-24h) or 
48 hours (SS-48h). At the end of each time point, the attached cells were harvested and 
DNA fragmentation was measured by a cell death ELISA assay. The data represent the 
mean ± SEM from three independent experiments. *, P<0.05, vs. NC or EV. 
F. The wild-type GSK-3β plasmid (GSK3βWT) or the empty vector (EV) was transiently 
transfected into C2C12 myoblasts growing in recombinant M-cadherin-Fc-coated (M-
cad-Fc) or vehicle-coated (Vehicle) dishes. 48 hours later, the cells were treated with 
serum starvation for another 48 hours before being harvested. A cell death ELISA assay 
was used to measure the DNA fragmentation in the harvested cells. The data represent 
the mean ± SEM from three independent experiments. *, P<0.05 vs. EV/Vehicle or 
EV/M-cad-Fc; †, P<0.05 vs. GSK-3βWT/Vehicle.  
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Figure 8. Effect of GSK-3β inhibition on cell-confluence-induced apoptosis.  
A. C2C12 myoblasts were grown to 80% confluency then transfected with an empty 
vector (EV) or GSK-3βK85R, which contained a V5 tag (left panel), or constitutively 
active Akt (myrAkt), (right panel) for 48h. Non-transfected cells normal control cells (NC) 
were cultured under identical conditions. The protein abundances of V5 tag, GSK-3β, 
and cyclinD1 were examined in GSK-3βK85R plasmid-transfected cells (left panel) and 
those of serine-437-phosphorylated and total Akt were examined in myrAkt plasmid-
transfected cells (right panel) by immunoblotting. 
B. C2C12 myoblasts were grown to 80% confluent then co-transfected with the M-
cadherin-targeted-siRNA (M-) plus myrAkt (M-/ myrAkt) or the GSK-3βK85R plasmid 
(M-/ GSK-3βK85R) or an empty vector (M-/EV).  Similar co-transfections were 
completed with the non-targeted scramble siRNA (SiCON) with myrAkt (SiCON/ 
myrAkt), GSK-3βK85R (SiCON/ GSK-3βK85R) or the empty vector (SiCON/EV).  Forty-
eight hours after transfection, the cells were harvested and processed for 
immunoblotting of cleaved caspase-9, cleaved caspase-3, and cleaved PARP.  GAPDH 
was used as a loading control. Each experiment was repeated three times.  
C. Densitometric analyses of immunoblots were obtained from C2C12 cells with 
identical treatments as described in Figure 5B. The data represent the mean ± SEM 
from three independent experiments. *, P<0.05, vs. SiCON/EV; †, P<0.05, vs. M-/EV.  
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Figure 9. Effect of GSK-3β inhibition on serum-starvation-induced apoptosis.   
A-C. Each experiment was repeated three times. *, P<0.05, vs. NC or SiCON. 
A. C2C12 cells were co-transfected with M-cadherin-targeted siRNA and one of the 
plasmids (myrAkt/GSK-3βK85R/empty vector) for 48 hours, then serum-starved for 48 
hours. DNA fragmentation was measured by an ELISA. †, P<0.05 vs. M-/EV.  
B. C2C12 cells were transiently transfected with M-cadherin-RNAi (M-), or a non-
targeted scrambled siRNA (SiCON). These were compared to normal non-transfected 
C2C12 cells (NC). The cells were treated with 20 µM TDZD-8 or DMSO for the last 12 
hours of siRNA transfection. Forty-eight hours after transfection, the treated and control 
cells were serum starved for 48 hours. The cells were harvested and DNA 
fragmentation was assessed by cell death ELISA. Each experiment was repeated three 
times. †, P<0.05 vs. SiCON/TDZD8 and the M-/DMSO.  
C. Mitochondria were isolated from each experimental group and stained with JC-1. The 
ratio of JC-1 orange/green staining was analyzed using a FACSCalibur system to 
measure the mitochondrial membrane potential. †, P<0.05 vs. M-/DMSO.  
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Figure 10. Effect of M-cadherin RNAi and GSK-3β inhibition on myogenic 
differentiation of C2C12 myoblasts. C2C12 cells were grown on coverslips, 
transfected with M-cadherin-targeted (M-) or non-targeted scrambled siRNA (SiCON) 
for 36 hours then incubated with or without TDZD-8 for 12 hours. The cells were then 
cultured in differentiation medium for 48 hours.  
A. Representative confocal images of C2C12 myoblasts after treatment with a 
combination of M-cadherin RNAi (M-) or non-targeted scrambled siRNA transfection 
(SiCON) and TDZD-8 or DMSO as a vehicle control. The cells were incubated in 
differentiation medium for 48 hours after the co-treatments. MyHC: red; DAPI: blue; 
TUNEL: green. Images were acquired at 20x. The scale bar = 100 μm.  
B-C. The data from three independent experiments were given as mean ± SEM. *, P< 
0.05 vs. SiCON/DMSO; †, P< 0.05 vs. M-/DMSO. 
B.  The myoblast fusion index was calculated for cells after each treatment described in 
Fig. 7A, as the ratio of the number of DAPI-positive nuclei located in the MyHC-positive 
myotubes (i.e., fused myoblasts) divided by the total number of nuclei in the same field.  
C. The apoptotic index was calculated as the percent of total nuclei that were TUNEL 
positive.  
 
 
 
 
 
 
 
 
116 
 
 
Figure 11 
 
 
 
 
 
 
 
 
 
 
 
117 
 
 
Figure 11 
 
 
 
118 
 
Figure 11 
 
 
 
119 
 
Figure 11. Effect of M-cadherin RNAi and GSK-3β inhibition on apoptosis and 
myogenic differentiation of primary Syndecan-4-positive myoblasts. Primary 
myoblasts were isolated from hindlimb muscles of 1-week old C57BL/6 mice and 
Syndecan-4-positive myoblasts were purified from isolated cells by fluorescence 
activated cell sorting (FACS).  
A. Approximately 20.2% cells of adult stem cells that were isolated from hindlimb 
skeletal muscles were Syndecan-4 positive (Top panel). The post-sort verification of 
FACS sorted cells indicated that the purity of Syndecan-4-positive cells was 97% 
(Bottom panel).   
B. Syndecan-4-positive myoblasts were grown on coverslips and treated as described 
in Fig. 7. The imaging of the cells was the same as in Fig. 7A. 
C-D.  The data from three independent experiments were given as mean ± SEM. *, P< 
0.05 vs. SiCON/DMSO. †, P< 0.05 vs. M-/DMSO. 
C. The myoblast fusion index was calculated as described in Fig. 7B. 
D. The apoptotic index was calculated as described in Fig. 7C.  
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Figure 12. M-cadherin knockdown reduces cell survival. C2C12 myoblasts were 
plated in 6 well plates at a density of 1.7x105 per well. 24 hours later, the cells were 
transfected with M-cadherin-targeted siRNA (M-) or non-targeted scrambled siRNA 
(SiCON). A group of non-transfected cells with identical culture condition was used as a 
normal control (NC). 48 hours after transfection, the cells were treated with serum 
starvation for 0 (SS-0h), 6 (SS-6h), 12 (SS-12h), 24 (SS-24h), or 48 hours (SS-48h). 
Phase contrast images were taken at the end of each time point prior to harvesting the 
cells for additional analyses.  The magnification of the microscope objective was 20x. 
The scale bar = 100 μm.  
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Figure 13. Immunoblotting analysis of cleaved caspases-9 in response to M-
cadherin RNAi plus serum starvation. The C2C12 cells were treated as described in 
Figure S1. The cells were harvested in RIPA buffer at the end of each time point and 
processed for immunoblotting.  
Top panel: Representative immunoblots are shown of cleaved caspase-9 in C2C12 
myoblasts after transfections with M-cadherin-targeted siRNA (M-), non-targeted 
scrambled siRNA (SiCON) or in non-transfected normal control cells (NC) after  0 (SS-
0h), 6 (SS-6h), 12 (SS-12h), 24 (SS-24h), or 48 hours (SS-48h) of serum starvation. 
GAPDH was probed as a loading control. Protein abundance of M-cadherin was 
detected to confirm the efficiency of  M-cadherin knock-down by siRNA.  
Bottom panel: Densitometric quantification of immunoblots from cleaved caspase-9 
protein abundance normalized to GAPDH. Each data point (mean ± SEM) is the mean 
of three independent experiments. *, a significant difference (p<0.05) from the NC and 
SiCON control groups. 
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Figure 14. Determination of transient transfection efficiency in C2C12 myoblasts. 
The transfection efficiency of the GSK-3β plasmid by FuGENE 6 in was estimated to be 
~20-30%. This was estimated by transfecting a pEGFP-C3 vector into C2C12 cells and 
counting the eGFP-positive cells in the fields 6-well plates of proliferating myoblasts with 
cell density ~ 70%~80% confluency were transfected with an EGFP-C3 vector (3ug per 
well) using either FuGENE 6 (Roche) (A) or DharmaFECT Duo (Thermo Scientific) (B). 
48 hours after transfection, eGFP-positive cells were visualized under a Nikon Eclipse 
TS100 microscope connecting to an X-Cite 120 fluorescence illumination system 
(Lumen Dynamics). Fluorescent images as well as phase-contrast images of the same 
field were captured using a SPOT RT camera (Diagnostic Instruments, Inc). The 
magnification of objective lens was 10x. The scale bar = 200 μm. 
 The transfection efficiency was estimated by counting eGFP-positive cells and total 
cells from ten random fields for either condition. The transfection rate was defined as 
number of eGFP-positive cells divided by the total number of cells within the same field. 
The transfection efficiency achieved by using FuGENE 6 in our experiments was 25.3% 
± 4.8%. The transfection efficiency using DharmaFECT Duo was 29.7% ± 5.4%. 
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Figure 15. Densitometric analyses of immunoblot band intensities of 
phosphorylated and total Akt and GSK-3β, survivin, and cyclin D1 in response to 
M-cadherin RNAi. C2C12 were transfected with M-cadherin-targeted siRNA (M-), non-
targeted scrambled siRNA (SiCON) or in non-transfected normal control cells (NC) and 
harvested 48 hours after transfection. Phosphorylated protein band intensities were 
normalized by those of corresponding total proteins (A, phospho-Akt/Akt; B, phospho-
GSK-3β/GSK-3β). The band intensities of survivin and cyclin D1 were normalized to 
GAPDH (C, Survivin/GAPDH; D, Cyclin D1/GAPDH). The data represent four separate 
experiments and show that the data are highly reproducible. 
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Figure 16. Densitometric analysis of immunoblot band intensities of 
phosphorylated and total Akt and GSK-3β, survivin, and cyclin D1 in response to 
recombinant M-cadherin-Fc treatment.  C2C12 myoblasts were grown in normal 
control (NC), vehicle control (Vehicle) or recombinant M-cadherin-Fc-coated (M-cad-Fc) 
dishes for 48 hours. The cells were lysed and subjected to immunoblotting analysis.  
Phosphorylated protein band intensities were normalized by those of corresponding 
total proteins (A, phospho-Akt/Akt; B, phospho-GSK-3β/GSK-3β). The band intensities 
of survivin and cyclin D1 were normalized to  GAPDH.  (C, Survivin/GAPDH; D, Cyclin 
D1/GAPDH). The data are shown from 3 separate experiments, and indicated that the 
results are repeatable. 
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Supplementary Detailed Materials and Methods 
 
Cell Culture 
C2C12 myoblasts were purchased from American Type Culture Collection (Manassas, 
VA) and maintained in Dulbecco Modified Eagle’s Medium (DMEM) (Invitrogen Life 
Technologies, Bethesda, MD) supplemented with 10% fetal bovine serum (FBS) and 
1% antibiotic and antimycotic mixture solution (Invitrogen), in a humidified incubator 
under an atmosphere of 5% CO2 at 37ºC. Serum starvation was carried out by culturing 
the cells in serum-free DMEM supplemented with 1% antibiotic and antimycotic mixture.  
 
Primary myoblasts were isolated from hind limb muscles of one-week old C57BL/6 mice 
using a modified protocol from Dr. Margaret Goodell’s lab (30). Briefly, the hindlimb 
muscles were minced and digested by 0.2% type II collagenase/HBSS at 37ºC. The 
minced muscle slurry was filtered with 40 µM cell strainers and myoblasts were 
separated from fibroblasts and other cell components by percoll (Sigma-Aldrich Co., St 
Louis, MO) gradient centrifugation. The Syndecan-4-positive myoblasts were further 
purified from isolated cells by fluorescence activated cell sorting (FACS) using a BD 
FACSAria (Benton Dickson Biosciences, San Jose CA) and anti-Syndecan-4 antibody 
(BD) with the program of BD FACS DIVA version 6.2. The Syndecan-4-positive primary 
myoblasts were cultured in Ham’s F10 supplemented with 20% FBS and 1% antibiotic 
and antimycotic mixture solution in a humidified incubator under an atmosphere of 5% 
CO2 at 37ºC. 
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Myogenic differentiation was induced by culturing the confluent C2C12 or primary 
myoblasts in differentiation medium composed of DMEM supplemented with 2% horse 
serum and 1% antibiotic and antimycotic mixture (Sigma-Aldrich).  
 
Chemical Inhibitors 
The PI3K inhibitor Wortmannin (working concentration: 200 nM) was obtained from 
Alexis Biochemicals (Plymouth Meeting, PA). GSK-3 inhibitor TDZD-8 (working 
concentration: 25 μM) was purchased from Sigma (St. Louis, Missouri). MEK1 inhibitor 
PD98059 (working concentration: 50 μM) was from Cell Signaling Technology (Danvers, 
MA). 
 
Inhibition of M-cadherin expression by RNA interference 
SMARTpool small interfering RNA (siRNA) targeted to M-cadherin mRNA (Life Thermo) 
consisted of duplex 1: sense: 5’-CGACACAGCUCUCAUCUAUUU-3’, antisense: 5’-PAU 
AGA UGA GAG CUG UGU CGU U-3’; duplex 2: sense: 5’-UAG AUG AUA UCA ACG 
ACA AUU-3’, antisense: 5’-PUU GUC GUU GAU AUC AUC UAU U-3’; duplex 3: sense: 
5’-GAA GGA CGG CUG GUA CAG AUU-3’, antisense: 5’-PUC UGU ACC AGC CGU 
CCU UCU U-3’; duplex 4: sense: 5’-CAG GAU GCA UAC GAC AUA AUU-3’, antisense: 
5’-PUU AUG UCG UAU GCA UCC UGU U-3’. The myoblasts were seeded in six-well 
plates 24 hours before transfection at a density of 1.7 × 105 per well. The transfection of 
siRNA was performed using either DharmaFECTTM-3 reagent (Life Thermo) (for C2C12 
myoblasts) or Lipofectamine 2000 (Invitrogen) (for primary myoblasts) according to the 
manufacturer’s instructions at a final siRNA duplex concentration of 100nM. The 
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efficacy of M-cadherin protein knockdown by RNA interference (RNAi) was confirmed 
by immunoblotting. 
 
Plasmids and Transfection 
The full-length mouse wild-type GSK-3β cDNA was generated by RT-PCR. mRNA was 
derived from wild C2C12 myoblasts using Trizol reagent (Life Technologies, Inc.) and 
reverse-transcribed into cDNA using Superscript II (Life Technologies, Inc.). The 
forward primer was 5’-TTC CCG CGG CCG CCG CCA TGT CGG GGC GAC CGA GAA 
C-3’, and the reverse primer was 5’-TTC CCT CTA GAT CAG GTG GAG TTG GAA 
GCT GA-3’, with recognition sites for restriction endonucleases NotI and EcoRI 
included. The PCR product was cloned into the expression vector pcDNA3.1/myc-His(-) 
(Invitrogen). The inserted region was verified by DNA sequencing (SeqWright, Inc., 
Houston, TX). The constitutively active mutant of Akt (myrAkt) and the V5-tagged 
kinase-deficient GSK-3β mutant (K85R) carried by vector pcDNA3 were generous gifts 
from Dr. Jia Luo (University of Kentucky). The wild-type GSK-3β plasmids were 
transfected into the cells using FuGENE 6 reagent (Roche Diagnostics, Indianapolis, IN) 
according to the manufacturer’s instructions. The co-transfection of M-cadherin siRNA 
with myrAkt or GSK-3β (K85R) plasmids was carried out using DharmaFECT Duo 
transfection reagent (Dharmacon, Inc., Thermo-Fisher Scientific, Lafayette CO) 
according to the manufacturer’s instructions.  
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Recombinant M-cadherin-Fc treatment 
 The recombinant M-cadherin-Fc chimera was purchased from R&D Systems. 6-well 
cell culture plates were pre-coated with goat anti-Fc antibody (0.5µg/cm2 in PBS/Ca2+; 
Jackson ImmunoResearch, West Grove, PA) overnight at 4°C followed by coating with 
recombinant M-cadherin-Fc chimera at a final concentration of 2µg/cm2 in 
0.1%BSA/PBS/Ca2+ for 2 hours at room temperature. The dishes were washed with 
PBS/Ca2+ and blocked with 1% BSA/HBSS/Ca2 for 1 hour. Plates coated with anti-Fc 
antibody only were used as vehicle control.  A number of 0.5 x 105 per well cells were 
plated and allowed to grow for 48 hours before being harvested for further assays.  
 
Subcellular fractionation 
The membrane fraction of C2C12 myoblasts was prepared using the Mem-PER 
eukaryotic membrane protein extraction reagent kit (Thermo Fisher Scientific, Rockford, 
IL) according to according to the manufacturer’s instruction. The nuclear protein fraction 
was prepared according to methods that have been previously described in our lab (31) 
with minor modifications. Briefly, the cells were harvested by trypsinization and 
incubated in lysis buffer (10mM NaCl, 1.5mM MgCl2, 20mM HEPES, pH 7.4, 20% 
glycerol, 0.1% Triton X-100, and 1mM dithiothreitol (DTT)) supplemented with protease 
and phosphatase inhibitor cocktails (Sigma-Aldrich, 1:100 dilution) with rotation at 4°C 
for 2 hours. The lysates were centrifuged at 2,500 rpm for 5 minutes at 4°C. The pellet 
containing nuclei portion was washed three times with lysis buffer and resuspended in 
nuclear lysis buffer containing 0.6M NaCl and incubated for another 2 hours at 4°C and 
centrifuged at 15,000 x g for 15 minutes. The supernatants contain the nuclear fraction. 
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The mitochondrial and mitochondria-free and nuclei-free cytosolic fractions were 
prepared using mitochondria/cytosol reagents (BioVision, Mountain View, CA) 
according to the manufacturer’s instruction. The concentration of the protein extracts 
was quantified in duplicate by Bio-Rad Dc Protein Assay (BioRad, Hercules, CA). The 
whole cell lysate was obtained by disrupting the cells with  RIPA buffer (mM NaCl, 1.0% 
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0) 
supplemented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich, 1:100 
dilution) followed by centrifugation at 10,000 rpm for 5 minutes at 4°C. The supernatant 
was collected as the whole cell lysate.  
 
Antibodies and immunoblotting 
Antibodies specific to phosphoserine 473 Akt,  total Akt, phosphoserine 9 GSK3β, total 
GSK3β, cytochrome c, cleaved caspase-9 and cleaved caspase-3, AIF, survivin (all the 
above antibodies were diluted by 1:1000) and cyclin D1 (1:2000 dilution) were 
purchased from Cell Signaling Technology (Danvers, MA). The anti-M-cadherin 
antibody (1:200 dilution) was obtained from Calbiochem (La Jolla, CA). The anti-
caspase-8 antibody (1:250 dilution) was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). The antibodies to histone H2B (1:5000 dilution), β-tubulin (1:500 
dilution) and GAPDH (1:5000 dilution) were obtained from Abcam (Cambridge, MA). 
The antibodies to Manganese superoxide dismutase (MnSOD) and Copper-Zinc 
superoxide dismutase (Cu-ZnSOD) (both diluted at 1:1000) were purchased from 
Millipore (Billerica, MA). The secondary antibodies for immunoblotting including goat 
anti-rabbit or goat anti-mouse IgG conjugated with horseradish peroxidase (HRP) were 
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obtained from Jackson ImmunoResearch Laboratories (West Grove, PA). The 
secondary antibodies were used at dilution ranges between 1:30000 and 1:100000. 
Immunoblotting of the cell fractions were conducted by diluting the cell lysates in 4X 
NuPAGE LDS sample buffer (Invitrogen) then heating them at 70°C for 10 min. Equal 
amount of proteins were loaded on to a 4-12% gradient polyacrylamide gel (Invitrogen) 
and separated by routine get electrophoresis. The proteins were transferred to a 
nitrocellulose membrane (Bio-Rad, Hercules, CA) and the membranes were blocked in 
5% non-fat milk or 5% bovine serum albumin dissolved in Tris buffered saline with 
0.05% Tween-20 (TBS-T) for 1 hour at room temperature. The membranes were probed 
with primary antibodies overnight at 4°C. The appropriate secondary antibody was 
applied to the membrane for 1 hour at room temperature. The resulting signals were 
developed using an enhanced chemiluminescence lighting (ECL) Western blotting 
detection reagent kit (GE Health Care, Piscataway, NJ). The resulting signals were 
visualized by exposing the membranes to X-ray films (BioMax MS-1; Eastman Kodak, 
Rochester, NY).  Digital records were obtained from each blot and the protein bands of 
interest were quantified using 1-D analysis software (Eastman Kodak).  The 
nitrocellulose membranes were stripped in a commercially available buffer (Millpore, 
Billerica, MA) and reprobed for β-tubulin, GAPDH, or Histone H2B as loading controls.  
 
Immunoprecipitation 
The cells were washed three times with ice-cold PBS and lysed in ice-cold buffer (150 
mM NaCl, 50 mM Tris, pH 7.5, 0.25% SDS, 0.1% Nonidet P-40) containing protease 
and phosphatase inhibitor cocktails, and centrifuged at 10,000 rpm for 5 minutes at 4°C. 
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The supernatants were collected and the protein concentration of each sample was 
determined by protein assay.  500 µg of each lysate was incubated with 10μg of mouse 
anti-PI3K-p85α (Abcam) or 2μg of rabbit anti-M-cadherin antibody (Santa Cruz) or 
mouse or rabbit IgG (Millipore) overnight at 4°C with rotation. The sample was then 
incubated with 20µl of Protein A/G PLUS-agarose beads (Santa Cruz) for 1 hour at 
room temperature with rotation. The beads were then collected by centrifugation at 
3,000 rpm for 1 minute and washed three times with ice-cold lysis buffer. The bound 
proteins were eluted from the agarose beads in 30ul of Laemmli sample buffer (5X) at 
95-100°C. The samples were centrifuged at 10,000rpm for 30 seconds and the 
supernatants were collected. The proteins were separated by SDS-PAGE and 
immunoblotted with antibodies against M-cadherin or PI3K-p85α.  
 
Microscopy, cell morphology and the myoblast fusion index 
Phase contrast microscopy. Phase contrast images of C2C12 and primary myoblast 
cells were captured using a Nikon Eclipse TS100 phase-contrast microscope (Nikon 
Instruments, Melville, NY) equipped with 10x/0.25 and 20x/0.40 phase contrast 
objectives and a SPOT RT camera, and analyzed with SPOT RT software (Diagnostic 
Instruments Inc., Sterling Heights, MI).  
 
Immunocytochemistry and Fluorescence microscopy. Immunocytochemical assays 
were conducted on cells that were grown on coverslips coated with 1% gelatin. The 
cells were fixed with fresh 4% paraformaldehyde/PBS, permeabilized with 0.5% Triton 
X-100/PBS, and then blocked with 1% BSA/PBS. The coverslips were then incubated at 
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4°C overnight with antibodies against mouse anti-M-cadherin (1:20 dilution, 
Calbiochem) or mouse anti-myosin heavy chain (MyHC) (1:500 dilution, Developmental 
Studies Hybridoma Bank, Iowa City, IA). The primary antibodies were diluted with 1% 
BSA/PBS.  After washing in PBS, the coverslips were incubated with the Alexa Fluor 
546 goat anti-mouse IgG (H+L) (Invitrogen) at 37°C for 1 hour. The nuclei were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI) and the cells were mounted in 
VECTASHIELD mounting medium (Vector Labs) and imaged with a Zeiss LSM510 
confocal on an AxioImager Z1 microscope using the Zeiss AIM software (Carl Zeiss 
MicroImaging, Thornwood, NY) and either a Plan-Apochromat 20x/0.8 objective or a 
Plan-Apochromat 63x/1.40 Oil objective, as indicated in the figure legends. The scan 
speed was 8 seconds and pinhole size was set at 1 Airy unit for each channel. 8-bit 
images (1024x1024) were sequentially acquired with equivalent settings (gain, offset, 
laser power, etc) for comparable intensity analysis. Tiff images (raw data) were 
exported and opened in Photoshop where the levels were adjusted equivalently across 
images.  
 
Myoblast fusion index. The myoblast fusion index was calculated as the ratio of the 
number of DAPI-positive nuclei located in the MyHC-positive myotubes (i.e., fused 
myoblasts) divided by the total number of nuclei in the same field. This fusion index was 
used as a read-out of myogenic differentiation. The fusion index was obtained from 10 
non-overlapping areas of each coverslip. 
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Apoptosis assays 
DNA fragmentation. DNA fragmentation was used to assess the level of apoptosis in 
muscle cells using an ELISA (Roche) which assessed cytosolic nucleosomes in 
attached cells. Measurements for DNA fragmentation were made at an absorbance of 
405nm. These methods have been described previously for our laboratory (31; 32). The 
data were normalized to the protein concentration of the sample.  
 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). A TUNEL 
assay (In Situ Cell Death Detection Kit; Roche) was used to identify the extent of 
apoptotic nuclei in adherent myoblasts as reported previously (33). The nuclei of all 
cells were counter-stained with DAPI. The number of TUNEL- and DAPI-positive nuclei 
was counted in ten images that were chosen randomly from non-overlapping areas of 
each group. The data were presented as the apoptosis index, which was determined by 
dividing total number of TUNEL-positive nuclei by the total number of DAPI-positive 
nuclei.  
 
As treatment with serum starvation and M-cadherin-siRNA resulted in apoptosis and cell 
death, some cells detached from the plates. To identify the full extent of apoptosis, and 
determine if M-cadherin-RNAi treatment increased the sensitivity of C2C12 myoblasts to 
serum starvation-induced apoptosis, we assessed apoptosis by a TUNEL assay in both 
adherent and floating cells in each well. The methods from Weyman’s group (4) were 
adapted as a third approach to quantify the apoptotic cells in both attached and floating 
cells. Briefly, floating cells were collected by centrifugation at 500x g for 5 minutes, 
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washed, and fixed in 4% paraformaldehyde for 20 minutes. Thereafter, the cells were 
permeabilized in 0.1% Triton X-100 for 2 minutes then incubated with TUNEL reagents 
using the In Situ Cell Death Detection Kit (Roche). Apoptotic cells in attached cells were 
labeled by TUNEL staining in a similar fashion. The total percent of apoptotic cells for 
each well was calculated as: (the total number of TUNEL-positive attached cells + the 
total number of TUNEL-positive floating cells) /(total attached cells + total floating cells).  
 
Cardiolipin content and mitochondrial membrane potential measurement 
Nonyl acridine orange (NAO, Invitrogen) was used to determine the cardiolipin content 
in the inner mitochondrial membrane as an indicator of mitochondrial integrity. C2C12 
myoblasts cultured on coverslips and transfected with M-cadherin-targeted or 
scrambled siRNA were incubated with NAO (250nM) at 37ºC for 20 minutes. 
Fluorescence was visualized with a Nikon Eclipse E800 fluorescence microscope 
equipped with a Plan Fluor 100x/1.30 Oil objective and images were captured using a 
SPOT RT camera (Diagnostic Instruments, Inc). The exposure time was constant for all 
images. The fluorescence intensity was analyzed and quantified using ImageJ 
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/, 1997-2011.). To measure changes in the mitochondrial 
membrane potential, mitochondria were isolated from M-cadherin RNAi or control cells 
and suspended in sucrose buffer (sucrose 220mM, mannitol 70mM, Tris HCl 10mM, 
EDTA 1mM, pH 7.4). The purity of mitochondria was verified by staining the 
mitochondria suspension with MitoTracker Deep Red 633 (Molecular Probes, Carlsbad, 
CA) at a final concentration of 100nM and analyzed by flow cytometry. This fluorescent 
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dye diffuses passively into intact and respiring mitochondria. Debris was excluded by 
appropriate gating strategies during flow cytometry analysis. The mitochondrial 
membrane potential (Δψmt) was measured by staining the mitochondria with 5,5',6,6'-
tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) (Molecular 
Probes) at a final concentration of 10ug/ml. The staining results of JC-1 orange/green 
were analyzed using a FACSCalibur system (BD Bioscience) using Cell Quest Pro. 4.0 
Software. 100,000 gated events were collected for each sample. 
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                                          ABSTRACT 
β-catenin is an essential molecule in both cadherin-mediated cell-cell adhesion and 
canonical Wnt signaling. The phosphorylation of β-catenin by GSK-3β at residues 
serine31/37/threonine41 of N-terminus regulates its stability and its role in canonical 
Wnt signaling. Recent work from our lab found that M-cadherin-mediated signaling 
protects myoblasts against apoptosis and promotes myogenic differentiation by 
suppressing GSK-3β activation. In this study, we further investigated the possibility that 
the N-terminal phosphorylation of β-catenin was regulated by M-cadherin and that this 
regulation mediates M-cadherin’s role in promoting myogenic differentiation. We 
demonstrated that knockdown of M-cadherin expression by RNA interference (RNAi) in 
C2C12 myoblasts significantly enhances the phosphorylation of β-catenin at 
ser33/37/thr41 and decreased the protein abundance of ser37/thr41-unphosphorylated 
active β-catenin. This effect can be relieved by LiCl treatment. Furthermore, M-cadherin 
RNAi promotes LiCl or Wnt-3a-induced TCF/LEF transcription activity but significantly 
blunts the myogenic induction by LiCl or Wnt-3a treatment. Knockdown of β-catenin 
expression by RNAi in C2C12 myoblasts also significantly decreased myogenic 
induction by LiCl treatment. Forced expression of phosphorylation-resistant mutated β-
catenin (S33Y-β-catenin) failed to enhance myogenic differentiation but partially 
rescued the myogenic and apoptotic phenotype caused by M-cadherin RNAi. These 
data show that M-cadherin-mediated signaling attenuates β-catenin phosphorylation at 
Ser31/37/Thr41 by GSK-3β and this regulation has a positive effect on myogenic 
differentiation induced by canonical Wnt signaling independent of TCF/LEF transcription 
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activity. Our findings provide a novel mechanism by which M-cadherin mediates 
myogenic differentiation. 
                                        INTRODUCTION 
β-catenin is a key transcription cofactor within the T cell factor/lymphoid 
enhancer factor (TCF/LEF) family of DNA binding proteins in the Wnt signaling pathway. 
It is also a central structural adaptor protein linking cadherins to the actin cytoskeleton in 
intercellular adherens junctions (1; 2). Without Wnt signaling, a sequential 
phosphorylation of β-catenin by serine/threonine kinases casein kinase Iα (CKIα) at 
serine45 and glycogen synthase kinase-3β (GSK-3β) at serine 33/37/threonine 41 
results in ubiquitination and degradation of cytoplasmic β-catenin. Activation of Wnt 
signaling leads to inactivation of GSK-3β, resulting in accumulation of cytoplasmic β-
catenin, which translocates to nucleus and binds to the TCF/LEF transcription factors to 
induce target gene expression. As a result, the key factors in β-catenin signaling include 
its stabilization and accumulation in the cytoplasm (3-5). β-catenin-mediated canonical 
Wnt signaling is crucial to muscle development (6; 7). One of the key mechanisms by 
which the β-catenin/Wnt pathway regulates myogenesis, is to induce the expression of 
basic helix-loop-helix (bHLH) myogenic regulatory factors (MRFs) such as Myf5 and 
MyoD (8; 9). The β-catenin/Wnt pathway is also essential for the myogenic specification 
of muscle-derived CD45-positive stem cells after injury (10) and differentiation of 
multipotent cells into myogenic cells (11; 12).  
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It is well established that a key role of the cadherins is to inhibit β-
catenin/canonical Wnt signaling (13-17). In addition to its direct binding and mechanical 
sequestering effect (18; 19), reports from several labs show that cadherins may also 
modulate β-catenin signaling via an adhesion-independent mechanism (13; 16; 17). 
Recent data from Gorttadi and colleagues suggest that E-cadherin directly promotes β-
catenin phosphorylation at N-terminus by GSK-3β in S2480 colon carcinoma cell lines 
(20), which in turn has an inhibitory effect on Wnt signaling. This provides a potential 
mechanism to explain how cadherins regulate β-catenin signaling function at least in 
cancer cells, although it is not know if this signaling would be similar in muscle cell lines. 
As a member of the classical cadherin family of transmembrane glycoproteins 
that mediates calcium-dependent homophilic cell-cell adhesion, M-cadherin has been 
shown to be crucial in mediating myoblast alignment and fusion (21; 22), and it is 
required for myogenic differentiation (23). We have recently reported that M-cadherin-
mediated signaling suppresses GSK-3β activation and protects myoblasts against 
intrinsic mitochondrial-dysfunction associated apoptosis during myogenic differentiation 
(24). However, the role for M-cadherin to regulate β-catenin phosphorylation at N-
terminus by GSK-3β in myoblasts and the potential impact that this regulation might 
confer to myogenic differentiation is unknown. 
In the present study, we investigated the regulatory effect of M-cadherin signaling 
on β-catenin N-terminal phosphorylation by GSK-3β and the impact of this regulation on 
myogenic differentiation. We show that knockdown of M-cadherin expression promotes 
TCF/LEF transcription activity but decreases the availability of N-terminal 
unphosphorylated signaling-active β-catenin in confluent C2C12 myoblasts. This effect 
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can be reversed by LiCl treatment. Furthermore, both M-cadherin and β-catenin RNAi 
abrogated the myogenic and fibrotic induction by LiCl treatment. Forced expression of a 
phosphorylation-resistant mutated β-catenin induces a dramatic increase in TCF/LEF 
transcription activity but failed to induce myogenic differentiation by itself. However, it 
partially rescued the myogenic and apoptotic phenotype caused by M-cadherin RNAi. 
Together, these results suggest that M-cadherin signaling suppresses GSK-3β-
dependent β-catenin N-terminal phosphorylation and promotes myogenic differentiation 
in a TCF/LEF-independent manner. 
                                MATERIALS AND METHODS 
Cell Culture 
C2C12 myoblasts were purchased from American Type Culture Collection 
(ATCC) and maintained in Dulbecco Modified Eagle’s Medium (DMEM) (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic and antimycotic 
mixture solution (Invitrogen), in a humidified incubator under an atmosphere of 5% CO2 
at 37ºC. Myogenic differentiation was induced by culturing the myoblasts in 
differentiation medium composed of DMEM, 2% horse serum and 1% antibiotic and 
antimycotic mixture. Recombinant Wnt-3a (working concentration: 50ng/ml) and 
recombinant Dickkopf-related protein (DKK-1, working concentration: 200ng/ml) were 
purchased from R&D Systems (Minneapolis, MN) for cell treatment. Lithium chloride 
(LiCl; working concentration: 20mM) was purchased from Sigma-Aldrich (St. Louis, 
MO). 
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Inhibition of M-cadherin and β-catenin expression by RNA interference 
SMARTpool small interfering RNA (siRNA) targeted to M-cadherin and β-catenin 
mRNAs were purchased from Dharmacon/Thermo Scientific (Lafayette, CO). The M-
cadherin-targeted siRNA consisted of duplexes targeting the following sequences: 5’-
CGACACAGCUCUCAUCUAU-3’; 5’-GAAGGACGGCUGGUACAGA-3’; 5’-
GAGCAAACGCUGAACGUCA-3’; 5’-UCGACGAGCACACGGGAGA-3’. The β-catenin-
targeted siRNA consisted of duplexes targeting the following sequences: 5’-
GAACGCAGCAGCAGUUUGU-3’; 5’-CAGCUGGCCUGGUUUGAUA-3’; 5’-
GCAAGUAGCUGAUAUUGAC-3’; 5’-GAUCUUAGCUUAUGGCAAU-3’. The myoblasts 
were seeded in six-well plates 24 hours before transfection at a density of 1.7 × 105 per 
well. The transfection of siRNA was performed using either DharmaFECTTM-3 reagent 
(when transfected alone) or DharmaFECTTM-Duo reagent (when co-transfected with 
plasmids) (Thermo Scientific) according to the manufacturer’s instructions at a final 
siRNA duplex concentration of 100nM.  
Plasmids and Transfection 
           The phosphorylation-resistant mutated β-catenin plasmid (pcDNA3-S33Y-β-
catenin), β-catenin/Wnt reporter plasmid super 8x TOPFlash, and its mutated control 
plasmid, super 8x FOPFlash, were purchased from Addgene (Cambridge, MA). The 
plasmids were extracted from bacteria and purified using EndoFree plasmid Maxi Kit 
(Qiagen). The plasmids were transfected into the cells using either FuGENE 6 reagent 
(Roche) (when transfected alone) or DharmaFECTTM-Duo (Thermo Scientific) (when co-
transfected with other plasmids or with siRNA) according to the manufacturer’s 
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instructions.  
Luciferase reporter assay  
Cells were transfected with 2µg of super 8xTOPFlash or FOPFlash reporter 
plasmid and allowed to grow for 24-36 hours before further treatment. And at the end of 
treatment, the cells were harvested in lysis buffer and 20 µl of each lysates was 
monitored for luciferase activity using a Luciferase Reporter Assay System (Promega, 
Madison, WI) according to the manufacturer’s instructions. Light units were measured 
using Berthold Autolumat Plus tube luminometer (Berthold Technology, Germany). The 
TCF/LEF transcription activity was determined as ratios of TOPFlash to FOPFlash 
luciferase activity from triplicate experiment.  
Cell surface biotinylation assay 
A cell surface biotinylation assay was used to quantify the subcellular 
(membrane-bound vs. membrane-free) protein abundance of β-catenin at different cell 
densities according to published protocols (25) with minor modifications. Briefly, the 
cells were washed three times with ice-cold PBS/Ca-Mg (138mM NaCl, 2.7 mM KCl, 1.5 
mM KH2PO4, 9.6 mM Na2HPO4, 1mM MaCl2, 0.1 mM CaCl2) and incubated with EZ 
link Sulfo-NHS-SS-biotin (1mg/ml, Pierce) in PBS/Ca-Mg for 30 min at 4°C. The 
reaction was quenched by two washes with ice-cold 100 mM glycine in PBS/Ca-Mg for 
10 min each and three times washes with ice-cold PBS/Ca-Mg. The cells was scraped 
from the dishes and lysed in ice-cold RIPA buffer containing protease inhibitor cocktail 
(Sigma, 1:100 dilution). The cell lysates were centrifuged at 15,000rpm for 30 min at 4 
°C, and aliquots of supernatants were incubated with streptavidin beads (Sigma, 25 µl 
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of beads for 500ug/500µl of aliquot) for 1 hour at 4°C with rotation. The beads were 
washed three times with ice-cold RIPA buffer. The bound proteins were eluted with 30ul 
of Laemmli sample buffer (5X) for 5 min at 95-100°C. The whole cell lysates and the 
unbound fractions were processed through the routine sample preparation procedure 
for immunoblotting.  
Antibodies and immunoblotting 
Antibodies that were specific to phosphorylated β-catenin 
(serine31/37/threonine41) and cyclin D1 were purchased from Cell Signaling 
Technology (Danvers, MA). An antibody to M-cadherin was from Calbiochem (La Jolla, 
CA). The antibody to the serine37/threonine41-unphosphorylated active β-catenin was 
purchased from Millipore (Billerica, MA). The antibody to total β-catenin was purchased 
from Sigma (St. Louis, MO). Antibodies to Axin2, Troponin T, and GAPDH were 
obtained from Abcam (Cambridge, MA). All the secondary antibodies for immunoblotting 
including goat anti-rabbit or goat anti-mouse IgG conjugated with horseradish 
peroxidase (HRP) were obtained from Jackson ImmunoResearch Laboratories (West 
Grove, PA). Immunoblotting of cell lysates were conducted according to established 
protocols in our lab  (24). Briefly, the cell lysates were diluted in 4X NuPAGE LDS 
sample buffer (Invitrogen) and boiled at 70°C for 10 min. Equal amount of proteins were 
loaded in a 4-12% gradient polyacrylamide gel (Invitrogen) and separated by 
electrophoresis. The proteins were transferred to a nitrocellulose membrane (Bio-Rad) 
and the membranes were blocked in 5% non-fat milk dissolved in Tris buffered saline 
with 0.05% Tween-20 (TBS-T) for 1 hour at room temperature and then probed with 
primary antibodies overnight at 4°C. This was followed by incubation with secondary 
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antibodies for 1 hour at room temperature. The resulting signals were developed using 
Amersham enhanced chemiluminescence lighting (ECL) western blotting detection 
reagent kit (GE Health Care) and exposed to films. The protein signals were captured 
with a digital camera (Kodak 290) with the KODAK 1D molecular imaging software. 
Densitometric analysis of immunoblot intensities was done using KODAK 1D molecular 
imaging software. 
Cell Imaging 
  For immunocytochemistry, cells were grown on coverslips coated with 1% 
gelatin. Cells ready for immunocytochemical staining were fixed with fresh 4% 
paraformaldehyde/PBS, permeabilized with 0.5% Triton X-100/PBS, blocked with 1% 
BSA/PBS. Primary antibodies were diluted with 1% BSA/PBS. The antibodies that were 
used for cell imaging were: mouse anti-β-catenin antibody (Sigma-Aldrich), rabbit anti-β-
catenin antibody (Cell Signaling), mouse anti-serine37/threonine41-unphosphorylated 
active β-catenin antibody (Millipore), mouse anti-myosin heavy chain (MyHC) antibody 
(Developmental Studies Hybridoma Bank), and rat anti-ER-TR7 antibody (Santa Cruz 
Biotechnology). The coverslips were incubated with the appropriate primary antibody at 
4°C overnight followed by incubation with the corresponding Alexa Fluor 546 or 488 
goat anti-mouse, anti-rabbit, or anti-rat IgG (H+L) (Molecular Probes) secondary 
antibody at 37°C for 1 hour. The nuclei were counter-stained with 4,6-diamidino-2-
phenylindole (DAPI) and the cells were mounted in VECTASHIELD mounting medium 
(Vector) and imaged with a Zeiss LSM510 confocal laser scanning microscope using 
AIM software (Carl Zeiss MicroImaging). The exposure time was 8 seconds and the 
hole size was set as 1. 
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Differentiation Index and Fusion Index 
  After 48-hours in differentiation the cells underwent the immunofluorescent 
staining of MyHC and nuclei as described above. The numbers of DAPI-positive nuclei 
were counted from 10 non-overlapping areas of each coverslip. The differentiation index 
was determined by calculating the ratio of the number of nuclei in MyHC-positive cells 
divided by the total number of nuclei in the same field. The fusion index was calculated 
as the ratio of the number of nuclei located in myotubes divided by the total number of 
nuclei in the same field (24; 26).  
Terminal deoxynucleotidyl  transferase dUTP nick end labeling (TUNEL) 
     A TUNEL assay (In Situ Cell Death Detection Kit; Roche) was used to identify the 
extent of apoptotic nuclei in adherent myoblasts as reported previously (27; 28). The 
nuclei of all cells were counter-stained with DAPI. The number of TUNEL- and DAPI-
positive nuclei was counted in ten images that were chosen randomly from non-
overlapping areas of each group. The data were presented as the apoptotic index, 
which was determined by dividing total number of TUNEL-positive nuclei by the total 
number of DAPI-positive nuclei.  
Statistical analyses 
The results are given as means ± standard error of mean (SE). Statistical analyses 
were performed using the SPSS 13.0 software package. A one-way analysis of variance 
(ANOVA) was used to compare differences in all measured variables. P < 0.05 was 
considered statistical significant. 
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                                            RESULTS 
GSK-3β-dependent phosphorylation of β-catenin N-terminus is reduced but 
TCF/LEF transcription activity is also down-regulated in C2C12 myoblasts at high 
cell density. β-catenin signaling and Wnt activity are regulated by cell confluence in 
various types of cells (29; 30). The expression level and pattern of cadherin proteins 
vary as the cell density changes. Cadherin is central partner that binds to β-catenin and 
in turn, regulates both the subcellular distribution and transcription activity of β-catenin. 
Thus to examine the phosphorylation status of β-catenin N-terminus by GSK-3β, mouse 
C2C12 mouse myoblasts were seeded at either 2.0 x103/cm2 to obtain a low density (~ 
20-30% confluent) or 2.1x104/cm2 to reach a high cell density (~100% confluent) within 
48 hours.  Immunoblot analyses showed that the protein abundance of phosphorylated 
β-catenin at residues serine33/37/threonine41 of N-terminus decreased, and those of 
“active” serine37/threonine41-unphosphorylated β-catenin and total β-catenin increased 
when cells were confluent (Figure 17A). In addition, the protein abundance of two target 
proteins for canonical Wnt signaling, Axin2 and cyclin D1, were decreased. We next 
examined the subcellular expression pattern of β-catenin at different cell densities. As 
shown in left panel of Figure 17B, β-catenin was located in both the nuclei and the cell 
cytoplasm, especially in perinuclear regions in cells at a low density. In contrast, β-
catenin was detected in the cytoplasm and also more prominently in adjacent cell-cell 
contacting regions when the cells were confluent (Figure 17B, right panel). The protein 
abundance of membrane-bound versus membrane-free β-catenin was then evaluated 
via a cell surface biotinylation assay. As shown in Figure 17C, the ratio of membrane-
bound/membrane-free β-catenin was significantly higher in cells that were grown at a 
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high cell density as compared with cells grown at a low density. This finding is 
consistent with the data showing that a large portion of β-catenin translocates to cell-cell 
adhesive membrane regions in confluent cells (Figure 17B). To examine the difference 
in canonical Wnt signal activity in cells at different densities, we plated and grew cells 
transfected with either the TOPFlash reporter vector or its mutant control FOPFlash 
vector, in either low or high cell densities as described in Materials and Methods.  As 
shown in Figure 17D, TCF/LEF transcription activity, as determined from the ratio of 
luciferase activity in TOPFlash vector-transfected cells normalized by that of FOPFlash 
vector-transfected cells, was significantly less in cells that were grown at high density, 
as compared with cells that were grown at a low density. However, in spite of the 
decreased TCF/LEF transcription activity, myogenic differentiation, as shown by 
immunofluorescent staining of myosin heavy chain (MyHC)-positive myotubes, was 
clearly enhanced in confluent C2C12 myoblasts as compared with cells that were grown 
at a low cell density in differentiation medium for 48 hours (Figure 17E). These data 
suggest that phosphorylation of β-catenin N-terminus by GSK-3β is suppressed, and 
TCF/LEF transcription is also down-regulated when C2C12 myoblasts become 
confluent. The high myogenic outcome of confluent myoblasts is independent of 
TCF/LEF transcription activity.  
M-cadherin RNAi increases phosphorylation of β-catenin N-terminus but has 
positive effect on TCF/LEF transcription activity. We have reported previously that 
M-cadherin-mediated signaling suppresses GSK-β activation in confluent myoblasts 
(24). To further investigate if M-cadherin-mediated signaling modulates GSK-3β-
dependent N-terminal phosphorylation of β-catenin, and the impact of this potential 
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modulation on TCF/LEF transcription activity in confluent C2C12 myoblasts, we 
inhibited M-cadherin expression in confluent C2C12 myoblasts via M-cadherin RNA 
interference (RNAi) and subsequently treated the cells with lithium chloride (LiCl), an 
established GSK-3β inhibitor and Wnt activator. LiCl inhibits GSK-3β activity by 
competing with ATP in the ATP-binding site of the kinase via directly competing with 
magnesium and by increasing the inhibitory phosphorylation of Serine 9 residue of 
GSK-3β (31). The protein abundance of phospho- and total β-catenin as well as the 
unphosphorylated active β-catenin (ABC) were analyzed by immunoblotting. As shown 
in Figures 18A and 18B, as the protein abundances of both total β-catenin and 
unphosphorylated active β-catenin were significantly increased in LiCl-treated cells, M-
cadherin RNAi aborted this effect (Figure 18B, middle and bottom panels). In addition, 
M-cadherin RNAi alone significantly increased the phosphorylation of β-catenin N-
terminus and LiCl treatment effectively reversed this induction (Figure 18B, top panel). 
Furthermore, compared with the scrambled siRNA-transfected group, M-cadherin RNAi 
alone did not alter the protein abundance of total β-catenin (Figure 18B, bottom panel) 
but decreased the abundance of unphosphorylated active β-catenin. This effect could 
be rescued by LiCl treatment (Figure 18B, middle panel). These results suggest that M-
cadherin-mediated signaling attenuates phosphorylation of β-catenin at N-terminus and 
maintains unphosphorylated active β-catenin in a GSK-3β-dependent manner. We 
further investigated the subcellular expression pattern of the unphosphorylated active β-
catenin in confluent myoblasts and the effect of M-cadherin RNAi and/or LiCl treatment 
on β-catenin via an immunofluorescence assay. Figure 18C shows that without LiCl 
treatment, β-catenin was localized primarily to cell-cell contact regions and in the cell’s 
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cytoplasm. Staining patterns with the anti-ABC antibody demonstrated that 
unphosphorylated active β-catenin mainly resides in the cytoplasmic space, but not at 
cell-cell contacting membrane regions. In addition, upon LiCl treatment, 
unphosphorylated active β-catenin but not total β-catenin translocates into nuclei 
(Figure 18C, (i) and (ii)). These results suggest that the unphosphorylated active form of 
β-catenin is most responsive to LiCl-induced Wnt activation.  However, M-cadherin 
RNAi did not alter the expression pattern of ABC and total β-catenin with or without LiCl 
treatment (Figure 18C, (iii) and (iv)). We further examined the change in TCF/LEF 
transcription activity in response to M-cadherin RNAi. As shown in Figure 18D, in spite 
of the decreased protein abundance of ABC, luciferase activity increased indicating that 
TCF/LEF transcription activity was increased in cells transfected with M-cadherin-
targeted siRNA compared with that in control groups. To further verify M-cadherin’s role 
in regulating TCF/LEF transcription activity, we co-transfected the cells with M-cadherin-
targeted siRNA and TOPFlash/FOPFlash-reporter plasmids and then treated the cells 
with either LiCl or recombinant Wnt-3a for 12 hours. The luciferase activity was 
measured in cells at the end of treatments. As shown in Figure 18E, both LiCl and Wnt-
3a treatment induced a significant increase in TCF/LEF transcription activity and both 
inductions were significantly enhanced in cells transfected with M-cadherin-targeted 
siRNA.  
M-cadherin RNAi blunts myogenic and fibrotic induction by LiCl treatment.  To 
further examine the effect of M-cadherin RNAi on the phenotype of myoblasts induced 
by LiCl treatment, C2C12 myoblasts transfected with either an M-cadherin-targeted or a 
scrambled non-targeted siRNA then treated with LiCl or recombinant Wnt-3a for 12 
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hours. This was followed by culture in differentiation medium for 48 hours to induce 
myogenic differentiation. The cells were then harvested for immunoblotting analysis. As 
shown in Figure 19A, the protein abundance of Troponin T, an established marker for 
terminal myogenic differentiation (32; 33), was significantly increased in LiCl or Wnt-3a-
treated cells compared with vehicle control cells. However, M-cadherin RNAi 
significantly attenuated the induction of Troponin T expression in both vehicle and 
LiCl/Wnt-3a-treated cells. Further morphological examination via immunofluorescent 
staining of MyHC-positive myotubes and nuclei (Figure 19B, top panel) showed that LiCl 
treatment induced a significant increase in both myogenic differentiation and fusion as 
determined by calculating the differentiation and fusion indexes. The myogenic 
differentiation and fusion inductions were both significantly blunted by M-cadherin RNAi 
(Figure 19B, middle and bottom panels). Since disregulated increases in Wnt signal 
could potentially skew the myogenic progenitor cells into fibrotic lineages (34; 35), we 
further examined the expression of a fibroblast marker, ER-TR7 (34; 36) in cells after 
the various treatments. As shown in Figure 19C, LiCl treatment induced a substantial 
increase in the expression of ER-TR7 in C2C12 myoblasts while M-cadherin RNAi 
effectively abrogated this induction. These results suggest that M-cadherin plays a 
positive role in mediating myogenic and fibrotic induction by Wnt signal activation 
caused by LiCl treatment.   
β-catenin RNAi and DKK-1 treatment reverses myogenic and fibrotic induction by 
LiCl treatment. To further verify the role of β-catenin/Wnt signaling in mediating 
myoblast phenotype induced by LiCl treatment, we treated the cells either with β-catenin 
RNAi to inhibit β-catenin expression, or with DKK-1, an established antagonist of 
158 
 
canonical Wnt signaling, followed by treating the cells with LiCl for 12 hours and culture 
in differentiation medium for 48 hours to induce myogenic differentiation. The cell 
morphology was examined by immunofluorescent staining of MyHC-positive myotubes 
and nuclei. The differentiation and fusion indices were determined and compared 
among cells after the appropriate treatments. As shown in Figure 20A, the increased 
myotube formation in LiCl-treated cells was largely prevented in β-catenin RNAi treated 
cells as both differentiation and fusion of myoblasts were significantly abrogated 
compared with LiCl treatment alone group. DKK-1 treatment has the similar antagonistic 
effect on LiCl treatment as β-catenin RNAi, although to lesser extent as compared with 
the change that was caused by β-catenin RNAi. Furthermore, both β-catenin RNAi and 
DKK-1 treatment significantly blocked the expression of the fibrotic marker, ER-TR7, 
which was induced by LiCl treatment (Figure 20B). These results provide convincing 
evidence that the myogenic and fibrotic induction by LiCl treatment is mediated by β-
catenin/Wnt signaling. 
Forced expression of phosphorylation-resistant mutated β-catenin partially 
rescued the blunting effect of M-cadherin RNAi on the LiCl-induced myogenic 
phenotype. To further clarify the role of the phosphorylation status of β-catenin N-
terminus in regulating myogenesis, we transfected a phosphorylation-resistant mutated 
β-catenin (S33Y-β-catenin) plasmid in C2C12 myoblasts and induced the myogenic 
differentiation for 48 hours after the transfection. Forced expression of S33Y-β-catenin 
in C2C12 myoblasts induced a significant increase in TCF/LEF transcription activity 
(Figure 21A) but failed to increase the protein abundance of Troponin T as determined 
by immunoblotting (Figure 21B), indicating that the expression of  the phosphorylation-
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resistant mutant form of β-catenin alone has no effect on myogenic differentiation of 
C2C12 cells. In contrast, LiCl treatment in cells that were co-transfected with both 
S33Y-β-catenin plasmid and M-cadherin siRNA, yielded an increased protein 
abundance of Troponin T compared with cells that were transfected with M-cadherin 
siRNA alone (Figure 21C). This suggests that the phosphorylation-resistant mutant form 
of β-catenin attenuates the blunting effect of M-cadherin RNAi on myogenic induction by 
LiCl treatment. 
Forced expression of phosphorylation-resistant (mutated) β-catenin partially 
attenuated apoptosis exacerbated by M-cadherin RNAi during myogenic 
differentiation. We have shown previously that M-cadherin RNAi exacerbated 
apoptosis in myoblasts during myogenic differentiation (24). We examined this further in 
an attempt to determine if the phosphorylation status of β-catenin N-terminus plays a 
role in regulating the apoptotic phenotype caused by M-cadherin RNAi.  M-cadherin-
targeted siRNA and S33Y-β-catenin plasmids were either transfected alone or co-
transfected into C2C12 myoblasts followed by culturing the cells in differentiation 
medium for 48 hours to induce myogenic differentiation. At the end of treatments, the 
cells were fixed and stained with an anti-MyHC antibody. In situ apoptotic DNA 
fragmentation was examined after staining the cells with terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL), and the nuclei were counter-stained with 
4',6-diamidino-2-phenylindole (DAPI) (Figure 22A). The indices for differentiation and 
apoptosis were calculated and compared among cells with different treatments. As 
shown in Figure 22, forced expression of S33Y-β-catenin alone did not alter the 
myogenic or the apoptotic outcomes in C2C12 cells at the end of 48-hour myogenic 
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differentiation. However, co-transfection of S33Y-β-catenin with M-cadherin siRNA 
partially rescued the impaired myogenic differentiation (Figure 22B) and attenuated the 
exacerbated apoptosis caused by M-cadherin RNAi alone (Figure 22C). These results 
suggest that alteration of the phosphorylation status of β-catenin N-terminus may 
mediate the apoptotic phenotype induced by disruption of M-cadherin-mediated 
signaling.  
                                       DISCUSSION 
 
This is the first study to show that by modulating N-terminal phosphorylation 
status of β-catenin, M-cadherin-mediated signaling regulates β-catenin/Wnt signaling 
and promotes myogenic differentiation in a TCF/LEF transcription-independent manner. 
In this study we report that M-cadherin RNAi increased GSK-3β-dependent 
phosphorylation of β-catenin N-terminus, decreased the protein abundance of 
unphosphorylated signaling-active β-catenin, and blunted myogenic induction caused by 
LiCl or Wnt-3a treatment. Forced expression of phosphorylation-resistant mutated β-
catenin alone failed to enhance myogenic differentiation but partially rescued the 
myogenic and apoptotic phenotype caused by M-cadherin RNAi. Interestingly, these 
effects are independent of changes in TCF/LEF transcription activity.  
The paired phosphorylation of β-catenin at NH2 terminus by CK1a and GSK-3β 
plays a crucial role in regulating β-catenin stability and signaling. β-catenin that is 
phosphorylated at residues 33 and 37 is recognized by the β-TrCP E3-ligase complex, 
resulting in its ubiquitylation and rapid degradation by the 26S proteasome (37). This is 
an important mechanism to turn off Wnt signaling. An accumulated body of evidence 
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suggests that N-terminus phosphorylation may directly modulate β-catenin-mediated 
signaling.  It has been demonstrated that Wnt signaling is specifically mediated by N-
terminal unphosphorylated β-catenin (38) and these N-terminal unphosphorylated β-
catenin  more readily accumulates in nuclei (39; 40). Thus the GSK-3β-dependent 
phosphorylation of β-catenin at N-Terminus may not only induce degradation as 
suggested by the classical view, but may also directly impact β-catenin transcriptional 
activity. Thus it is possible that the phosphorylation status alone may regulate β-catenin-
mediated Wnt signaling without affecting its stability. Indeed, we demonstrated in this 
study that the unphosphorylated active β-catenin (ABC) mainly accumulates in 
cytoplasm regions and not at cell-cell contacts in confluent myoblasts. In response to 
LiCl treatment, ABC but not total β-catenin translocates into nuclei, indicating that ABC 
is more responsive to Wnt stimulation. 
It is clear that cadherin proteins modulate β-catenin transcription activity in a 
variety of cells. For example, binding of β-catenin to the cadherin cytoplasmic tail has 
been shown to inhibit β-catenin degradation and efficiently block its transactivation in 
Chinese hamster ovary and SW480 colon carcinoma cell lines (41). In addition, 
transient expression of exogenous E-cadherin in both epithelial and fibroblastoid cells 
has been reported to arrest cell growth via inhibiting β-catenin transcriptional activity 
(42). Furthermore, knockdown of E-cadherin in DLD-1 colorectal cancer cells, which 
have constitutive activation of Wnt signaling and exhibit E-cadherin-mediated cell 
adhesion, resulted in translocation of β-catenin to the nucleus and an enhancement of 
β-catenin/TCF-dependent reporter activity (43). In L929 fibroblasts, which are deficient 
in Wnt signaling and E-cadherin-based cell contacts, ectopic expression of E-cadherin 
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induced the stabilization of β-catenin at the cell junctions and caused marked alterations 
in cellular morphology and phenotype but no significant change in the transcriptional 
program of these cells in the absence of Wnt signaling. Furthermore, expression of wild-
type E-cadherin significantly inhibits the growth of SW480 colon carcinoma cells via 
inhibiting β-catenin/TCF gene promoter activity in an adhesion-independent manner 
(44), whereas, that restoration of E-cadherin expression in these cells enhances the 
phosphorylation status of β-catenin N-terminus and suppresses the Wnt signaling in the 
cells.  Similar to our observation in myoblasts, several other labs have demonstrated 
that  β-catenin translocates to cell-cell junctions and this increase occurs during the 
initiation of myogenic differentiation (45). In addition, expression of a short 23-amino-
acid segment of the cadherin cytoplasmic tail in mammalian cells does not affect cell-
cell junctions but effectively inhibits β-catenin-mediated signaling (46). As RhoA activity 
is required for β-catenin recruitment to intercellular adhesions sites (47), it is important 
to note that N-cadherin-dependent cell-cell contact activates muscle-specific promoters 
and RhoA in C2C12 cells. To this point, no study has evaluated how M-cadherin 
regulates the phosphorylation status of the N-terminus of β-catenin, nor examined the 
impact of this regulation on myogenic differentiation.  Our results in the current study 
show that inhibition of M-cadherin expression by RNAi increases phosphorylation of the 
N-terminus of β-catenin, decreases the protein abundance of unphosphorylated active 
β-catenin, and impairs the myogenic induction that is caused by either LiCl or Wnt-3a 
treatment. Together these results indicate that M-cadherin-mediated signaling 
attenuates GSK-3β-dependent phosphorylation of the β-catenin N-terminus and helps in 
maintaining a cytosolic pool of unphosphorylated signaling-active β-catenin, which plays 
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a critical role in myogenic induction by Wnt stimulation. Interestingly, the positive role of 
M-cadherin on N-terminal unphosphorylated active β-catenin and Wnt signaling in 
myoblasts that is demonstrated in our study is different from the findings from another 
study that reported a negative regulatory role of restored E-cadherin expression on ABC 
and Wnt signals in colon carcinoma cells.  A possible explanation for this discrepancy is 
that the regulatory role of cadherin on β-catenin phosphorylation is cadherin-type and 
cell-context dependent. The exact mechanism by which M-cadherin-mediated signaling 
attenuates phosphorylation of β-catenin at the N-terminus remains to be elucidated. We 
have shown previously that M-cadherin suppresses GSK-3β activity in confluent 
myoblasts (24). In the present study we further demonstrate that while a large portion of 
β-catenin is detected at cell-cell contact membrane regions, in confluent myoblasts, 
unphosphorylated active β-catenin is located mainly in cytoplasmic regions of the cell 
rather than at cell-cell contacts. This observation suggests that the phosphorylation 
regulatory effect by M-cadherin is not simply a result of direct binding to 
unphosphorylated active β-catenin, but rather in an adhesion-independent manner. 
Furthermore, M-cadherin RNAi increases phosphorylation of the β-catenin N-terminus 
and decreases the protein abundance of unphosphorylated active β-catenin. Inhibition 
of GSK-3β by LiCl treatment significantly reverses this effect. These results indicate that 
M-cadherin-mediated signaling attenuates phosphorylation of β-catenin N-terminus 
through suppressing GSK-3β activity. 
Our results show that the myogenic potential is much higher in confluent 
myoblasts as compared with cells with a low density, but the TCF/LEF transcription 
activities change in the opposite way. In addition, although knockdown of M-cadherin by 
164 
 
RNAi promotes TCF/LEF transcription activity at both steady state and LiCl/Wnt-3a-
treatment conditions, it blunts the myogenic differentiation under those conditions. While 
forced expression of the phosphorylation-resistant mutant form of β-catenin induced a 
substantial increase in TCF/LEF transcription activity, it failed to induce a similar 
increase in myogenic differentiation by itself. These results show that there is a 
disconnection between the level of TCF/LEF transcription activity and the outcome of 
myogenic differentiation in myoblasts, suggesting that β-catenin may mediate Wnt 
signaling and promote myogenic differentiation independent of its role in enhancing 
TCF/LEF transcription activity.  These findings are however, consistent with reports 
from treated LIM2537 cells, a poorly-differentiated colon cancer cell line, which when 
they are treated with the potent differentiating agent sodium butyrate, reduces GSK-3β 
activity by 34%, stabilizes the level of cytoplasmic β-catenin but there is no increase in 
β-catenin/TCF target genes c-myc and cyclin D1 (48). Previous work has shown that β-
catenin interacts with I-mfa (an inhibitor of the MyoD family of muscle regulatory 
transcription factors (MRFs)) and this interaction relieved the transcription activity 
suppression and cytosolic sequestration of MRFs by I-mfa (11). This observation 
suggests that a β-catenin-dependent but TCF/LEF-independent regulatory mechanism 
impacts MRFs during myogenesis. Similarly, Kim and colleagues  (49)  reported that 
TCF/LEF activity is dispensable for β-catenin’s role in promoting myogenic 
differentiation. Instead, β-catenin directly interacts with MyoD and enhances its 
transcriptional activity that is necessary for myogenic differentiation (49). Interestingly, 
the results in our present study show that TCF/LEF transcription activity is increased in 
response to M-cadherin RNAi in spite of the decreased availability of unphosphorylated 
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active β-catenin, suggesting that TCF/LEF transcription activity might be more 
responsive to the relief of mechanical sequestration of β-catenin by M-cadherin caused 
by M-cadherin knockdown and less dependent on the change in phosphorylation status 
of β-catenin N-terminus, at least in C2C12 myoblasts. 
Along with Notch signaling, the β-catenin/Wnt signaling pathway plays a critical 
role in regulating myogenic differentiation (34; 35; 50; 51). Although skeletal muscle 
progenitor cells are committed to be  myogenic  lineages and do not spontaneously 
adopt non-myogenic fates (52), it has been reported that hyper-activation of Wnt 
signaling may induce the premature termination of the expansion of myogenic 
progenitor cells and push the myogenic progenitor cells towards fibroblast lineages, 
resulting in the increased fibrosis in muscle tissues (34; 35). Indeed, we demonstrated 
that treating C2C12 myoblasts with LiCl before culturing them in differentiation medium 
gave rise to the expression of a fibroblast marker, ER-TR7. The fibrotic induction 
caused by Wnt stimulation via LiCl treatment could be effectively reversed by inhibition 
of the expression of either M-cadherin or β-catenin.   
We have shown previously that knockdown of M-cadherin expression via RNAi in 
both C2C12 myoblasts and primary muscle progenitor cells exacerbates apoptosis 
during myogenic differentiation. This increase in apoptotic signaling was partially 
rescued by inhibition of GSK-3β activity (24). In the current study, we further 
demonstrated that M-cadherin RNAi increased phosphorylation of β-catenin N-terminus 
and forced expression of the phosphorylation-resistant mutated β-catenin partially 
rescued the apoptosis induced by M-cadherin RNAi. These observations suggest that 
alteration in the phosphorylation levels of β-catenin N-terminus and β-catenin/Wnt 
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signaling might be at least partially responsible for mediating M-cadherin RNAi-induced 
apoptosis during myogenic differentiation. Our findings here are consistent with reports 
from other groups that show that β-catenin/Wnt signaling plays an important role in 
promoting survival of either skeletal or cardiac myoblasts under various conditions (53-
56).  
In conclusion, the data in the present study show that M-cadherin-mediated 
signaling attenuates phosphorylation of β-catenin N-terminus and helps in maintaining a 
cytosolic pool of N-terminal unphosphorylated signaling-active β-catenin which plays a 
key role in mediating canonical Wnt signaling to promote myogenic differentiation in a 
TCF/LEF-independent manner. 
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Figure 17. Phosphorylation and subcellular distribution of β-catenin, TCF/LEF 
transcription activity, and myogenic differentiation in C2C12 myoblasts at 
different cell densities.  
A. C2C12 myoblasts were plated at either a low density (2.0 x103/cm2), or a high 
density (2.1x104/cm2). 48 hours after plating, the cells were harvested in lysis buffer for 
immunoblotting analysis of the protein abundance of phosphorylated (Ser33/37/Thr41), 
Ser37/Thr41-unphosphorylated active β-catenin (ABC) and total β-catenin. Protein 
abundance of Axin2 and cyclin D1 were also examined. GAPDH was used as a loading 
control. 
B. Representative confocal images of β-catenin staining in C2C12 myoblasts at low or 
high cell density as described in Figure 1A. The objective magnification is 63x. The 
length of scale bar is 10μm.   
C. Top panel: Representative immunoblots of protein abundance of β-catenin in 
subcellular fractions (membrane-bound versus membrane-free) of cells at low or high 
density as determined by cell surface biotinylation assay. Bottom panel: determination 
and comparison of ratios of β-catenin in membrane-bound fraction to that in membrane-
free fraction in cells of different densities. Each data point (mean ± SEM) is the mean of 
three independent experiments. *, P< 0.05 vs. the low density group. 
D. C2C12 myoblasts transfected with either a TOPFlash or a FOPFlash plasmid. The 
cells were then plated at low or high cell density. 48 hours later the cells were harvested 
for luciferase activity measurement to determine the TCF/LEF transcription activity. 
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Each data point (mean ± SEM) is the mean of three independent experiments. *, P< 
0.05 vs. the low density group. 
E. Representative images of MyHC-positive myotubes in cells at low or high density 
after culture in differentiation medium for 48 hours. MyHC: red; DAPI: blue. Images 
were acquired at 20x. The scale bar = 100 μm.  
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Figure 18.  Effect of M-cadherin RNAi and LiCl treatment on β-catenin 
phosphorylation and subcellular distribution, and TCF/LEF transcription activity.  
A. Representative immunoblots of protein abundance of phospho-, unphosphorylated 
active β-catenin (ABC) and total β-catenin in C2C12 myoblasts in either M-cadherin 
siRNA-transfected (M-) or non-targeted scrambled siRNA-transfected (SiCON) cells 
treated with LiCl (20mM) or PBS as a vehicle control for 12 hours. Non-treated cells with 
same culture condition were used as a normal control (NC). GAPDH was probed as a 
loading control.  
B. Top panel: Densitometric analyses of immunoblots of phospho-β-catenin normalized 
to GAPDH. *, P< 0.05 vs. the SiCON plus Vehicle group.  †, P< 0.05 vs. M- plus vehicle 
group. Middle panel: Densitometric analyses of immunoblots of ABC normalized to 
GAPDH. *, P< 0.05 vs. the SiCON plus Vehicle group. †, P< 0.05 vs. M- plus vehicle 
group. Bottom panel: Densitometric analyses of immunoblots of total β-catenin 
normalized to GAPDH. *, P< 0.05 vs. the SiCON plus Vehicle group.  †, P< 0.05 vs. 
SiCON plus LiCl group. 
C. Representative confocal images of immunofluorescent staining of ABC and total β-
catenin in M-cadherin-RNAi-treated (M-) or non-targeted scrambled siRNA-transfected 
(SiCON) cells that were treated with PBS or LiCl for 12 hours.  ABC: green; β-catenin: 
red; DAPI: blue. Images were acquired at 63x. The length of scale bar is 10μm.           
D. TCF/LEF transcription activity in M-cadherin-RNAi (M-), non-targeted scrambled 
siRNA-transfected (SiCON) or normal control (NC) C2C12 myoblasts as determined by 
TOPFLASH/FOPFLASH luciferase activity. *, P< 0.05 vs. the control groups.            
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E. TCF/LEF transcription activity in M-cadherin-RNAi (M-), non-targeted scrambled 
siRNA-transfected (SiCON) or normal control (NC) C2C12 myoblasts that were treated 
with LiCl (20mM) or recombinant Wnt-3a (50ng/ml) for 12 hours as determined by 
TOPFLASH/FOPFLASH luciferase activity. *, P< 0.05 vs. the normal control (NC) 
group.  **, P< 0.01 vs. NC group. †, P< 0.05 vs. the SiCON plus LiCl treatment group. #, 
P< 0.05 vs. the SiCON plus Wnt-3a treatment group.           
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Figure 19.  Effect of M-cadherin RNAi and LiCl treatment on myogenic and fibrotic 
outcome in C2C12 myoblasts. 
A, Top panel: Representative immunoblots of protein abundance of Troponin T, an 
established marker for terminal myogenic differentiation, in M-cadherin-RNAi-treated 
(M-) or non-targeted scrambled siRNA-transfected (SiCON) cells that were treated with 
LiCl (20mM), recombinant Wnt-3a (50ng/ml), or DMSO as a vehicle control for 12 hours, 
followed by culture in differentiation medium for 48 hours. GAPDH was probed as a 
loading control. Bottom panel: Densitometric analysis of immunoblots of Troponin T 
normalized to GAPDH. *, P< 0.05 vs. the SiCON plus Vehicle group. #, P< 0.05 vs. M- 
plus Vehicle group. †, P< 0.05 vs. the correspondent vehicle/LiCl/Wnt-3a-treatment in 
SiCON groups.                
B, Top panel: Representative confocal images of MyHC-positive C2C12 myotubes after 
treatments with PBS, or LiCl, or LiCl plus M-cadherin RNAi (LiCl plus M-), followed by 
culture in differentiation medium for 48 hours. MyHC: red; DAPI: blue. Images were 
acquired at 20x. The length of scale bar is 100μm. Middle panel: The differentiation 
index was determined and compared among cells with above treatments. Bottom panel: 
The fusion index was determined and compared among cells with above treatments. *, 
P< 0.05 vs. the PBS-treated group. †, P< 0.05 vs. the LiCl-treated group.                
C. Top panel: Representative confocal images of immunofluorescent staining of a 
fibrotic marker, ER-TR7, in C2C12 myoblasts with treatments as described in figure 3B.  
ER-TR7: green; DAPI: blue. Images were acquired at 20x. The length of scale bar is 
100μm. Bottom panel: Quantitative analysis of mean fluorescence intensity of ER-TR7 
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staining in cells with above treatments. *, P< 0.05 vs. the PBS-treated group. †, P< 0.05 
vs. the LiCl-treated group. 
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Figure 20.  The effect of β-catenin RNAi and DKK-1 treatment on myogenic and 
fibrotic induction by LiCl treatment. 
A. Top panel: Representative confocal images of MyHC-positive C2C12 myotubes after 
treatments of β-catenin RNAi, or SiCON, or DKK-1(200ng/ml), followed by LiCl 
treatment for 12 hours and culture in differentiation medium for 48 hours. MyHC: red; 
DAPI: blue. Images were acquired at 20x. The length of scale bar is 100 μm. Middle 
panel: Differentiation index among cells with above treatments. Bottom panel: Fusion 
index among cells with above treatments. *, P< 0.05 vs. the LiCl plus SiCON group.    
B. Top panel: Representative confocal images of immunofluorescent staining of ER-
TR7 in C2C12 myoblasts with treatments as described in Figure 5A.  ER-TR7: green; 
DAPI: blue. Images were acquired at 20x. The length of scale bar is 100 μm. Bottom 
panel: Quantitative analysis of mean fluorescence intensity of ER-TR7 staining in cells 
with above treatments. *, P< 0.05 vs. the LiCl plus SiCON group.  
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Figure 21. The effect of forced expression of phosphorylation-resistant mutated 
S33Y-β-catenin on TCF/LEF transcription activity and myogenic differentiation. 
A. TCF/LEF transcription activity in S33Y-β-catenin plasmid-transfected (S33Y-B-CAT), 
empty vector-transfected (EV) or untreated normal control (NC) C2C12 myoblasts was 
determined by measuring TOPFLASH/FOPFLASH luciferase activity. *, P< 0.01 vs. the 
control groups.            
B. Representative immunoblots of protein abundance of Troponin T in S33Y-β-catenin-
transfected (S33Y-B-CAT), empty vector-transfected (EV) or normal control (NC) 
C2C12 myoblasts after culture in differentiation medium for 48 hours. GAPDH was 
probed as a loading control.   
C. Top panel: Representative immunoblots of protein abundance of Troponin T in the 
following four groups of cells: normal control (NC), LiCl-treated (LiCl), LiCl plus M-
cadherin siRNA-transfected (LiCl/M-), LiCl plus M-cadherin-siRNA and S33Y-β-catenin 
plasmid-co-transfected (LiCl/M-/S33Y-B-CAT), and differentiation for 48 hours. Bottom 
panel: Densitometric analyses of immunoblots of Troponin T normalized to GAPDH. *, 
P< 0.05 vs. NC group.  #, P< 0.05 vs. LiCl group.  †, P< 0.05 vs.  LiCl plus M- group. 
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Figure 22.  Effect of forced expression of phosphorylation-resistant mutated 
S33Y-β-catenin on apoptosis and myogenic differentiation in response to M-
cadherin RNAi.  
C2C12 cells were grown on coverslips, co-transfected with M-cadherin-targeted (M-) or 
non-targeted scrambled siRNA (SiCON) with S33Y-β-catenin plasmid (S33Y-B-CAT) or 
an empty vector (EV) for 36 hours. The cells were then cultured in differentiation 
medium for 48 hours.  
A. Representative confocal images of immunofluorescent staining MyHC-positive 
C2C12 myotubes with treatments as described above. In situ DNA fragmentation was 
labeled by TUNEL staining. MyHC: red; TUNEL: green; DAPI: blue. Images were 
acquired at 20x. The scale bar = 100 μm.  
B. The differentiation index of C2C12 cells that were exposed to the above treatments. 
*, P< 0.05 vs. SiCON/EV group.  †, P< 0.05 vs.  M-/EV group. 
C. The fusion index of C2C12 cells exposed to the treatments described above. *, P<  
0.05 vs. SiCON/EV group.  †, P< 0.05 vs.  M-/EV group. 
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CHAPTER 4: 
General discussion, conclusion and future studies 
 
 
 
 
 
 
 
 
 
 
202 
 
4.1. General discussion and conclusion. Skeletal muscle comprises about 40% of 
human body weight, and plays a key role in various functions including locomotion, 
maintenance of posture, respiration (diaphragm and intercostals contractions), 
communication (by verbal and facial muscles), thermogenesis and regulation of 
metabolism (1). Mammalian skeletal muscle is comprised of multinucleated myofibers 
that are formed by fusion of mononucleated myoblasts during embryonic development. 
As a contractile tissue that undergoes repeated contraction, damage occurs frequently 
to muscles due to the wear and tear during repeated contractions, especially in 
response to lengthening contractions. However, adult skeletal muscle is able to 
regenerate and repair the injury. Thus muscle regeneration is critical for maintenance of 
adult muscle mass, quality and performance.   
A population of muscle precursor cells known as satellite cells, function as stem 
cells in adult skeletal muscle and are critical for muscle regeneration. In addition,  
growth and regeneration of muscle as a postnatal tissue requires additional myonuclei 
from outside of myofibers since myonuclei are post-mitotic (2). Satellite cells serve as 
the primary source for the addition of new myonuclei to adult muscle tissue (3). The 
decrease in both number and function of satellite cells is one of the major cellular 
mechanisms for various muscular wasting disorders including sarcopenia. It is one of 
the long term research focuses in the Alway lab to get a better understanding on the 
mechanism of sarcopenia. Previous findings in the Alway lab have identified an 
association between increased apoptotic signaling and the occurrence and progression 
of sarcopenia (4-9). The overall purpose of this study is to extend the investigation of 
the association between apoptosis regulation and muscle regeneration to a cellular and 
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molecular level, and to get further insights in the molecular mechanism of apoptotic 
regulation of myoblasts and the effect of this regulation on myogenic differentiation and 
adult muscle regeneration. Understanding the regulatory role of M-cadherin in apoptosis 
and Wnt signaling was one of the primary goals of this research. Although an in vivo M-
cadherin knockout model suggests that M-cadherin is dispensable for myogenesis and 
muscle regeneration (10), the extensive potential compensations that occur in a 
genetically engineered animal model may not fully represent the consequences caused 
by a gene down-regulation that occurs in an adult context. For example, MyoD and 
Myf5, are both myogenic regulatory factors (MRFs) that are important in regulating the 
behavior of satellite cells. MyoD determines the myogenic capability of myoblasts (11; 
12), whereas Myf5 plays a major role in regulating their self-renewal and homeostasis 
(13; 14). Interestingly, although either MRF can compensate for the loss of the other 
during embryogenesis, they fail to compensate for each other in an adult context. The 
same mechanism might also apply to the interpretation of the redundancy among 
different types of cadherins. Although the loss of M-cadherin appears to be well 
compensated during embryogenesis, the same compensation by other types of 
cadherins may not occur as the gene expression of M-cadherin is down-regulated in 
adult muscle. This speculation is supported by findings from in vitro studies from 
different groups which reported  that M-cadherin promotes myoblast fusion (15; 16) and 
is indispensable for myogenic differentiation (17). In addition, in spite of the important 
role of cadherin in regulating apoptosis and canonical Wnt signaling in other types of 
cells and tissues, there is no report that addresses how M-cadherin modulates 
apoptosis and Wnt signaling in myoblasts. The study presented in Chapter 2 is the first 
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report to show that M-cadherin protects myoblasts against apoptosis during myogenic 
differentiation. We demonstrated that M-cadherin-mediated cell-cell adhesion activates 
PI3K/Akt and enhances the inhibitory phosphorylation of GSK-3β at serine 9, 
suppresses the occurrence of MOMP and protects the cells against mitochondria-
associated intrinsic apoptosis during myogenic differentiation (Figure 4.1). Furthermore, 
as the data presented in Chapter 3, this is the first study to show that by modulating the 
GSK-3β-dependent phosphorylation of β-catenin at the N-terminus, M-cadherin-
mediated signaling helps in maintaining a signaling-active N-terminal unphosphorylated 
β-catenin, which is critical in mediating the myogenesis-promoting effect of canonical 
Wnt signaling in a TCF/LEF-independent manner (Figure 4.1). 
            Substantial evidence shows that apoptosis is a coincident event that occurs 
during cell differentiation in many types of cells including myoblasts (18). Indeed, a 
substantial portion of myoblasts die by apoptosis whereas other ones survive by 
differentiation and fusion into myotubes (18-22). The underlying mechanism and 
signaling pathways controlling the life and death decisions of differentiating cells are 
largely unknown and therefore the object of intensive investigation. It is known that 
proper mitochondria function is critical in myogenic differentiation (23-25). Furthermore, 
there is a difference in mitochondrial membrane potential between myoblasts 
undergoing apoptosis and myoblasts that successfully differentiate (26). The current 
study demonstrates that M-cadherin-mediated signaling plays an important role in 
maintaining the mitochondrial integrity of differentiating myoblasts and regulates 
apoptosis during myogenic differentiation. We show that inhibition of M-cadherin 
expression by RNAi sensitized C2C12 myoblasts to mitochondria-associated intrinsic 
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apoptosis that was triggered by cell confluence and serum starvation. This observation 
suggests that M-cadherin-mediated signaling regulates mitochondrial integrity and 
function in myoblasts.   
            Cadherin is an established inhibitor for β-catenin/canonical Wnt signaling in 
various types of cell contexts. It inhibits β-catenin activity by three ways: mechanical 
sequestration, direct inhibition of its transcription activity, and promoting its N-terminus 
phosphorylation by GSK-3β (in colon cancer cells) (27). Interestingly, different from the 
finding in a colon cancer cell line, we found in myoblasts that M-cadherin-mediated 
signaling attenuates the phosphorylation of β-catenin N-terminus and promotes β-
catenin activity in a TCF/LEF-independent manner. This observation adds a novel 
mechanism to the regulation of β-catenin by cadherins. In addition, the data in chapter 3 
demonstrates that hyperactivation of Wnt signaling caused by LiCl treatment induces 
both myogenic differentiation and a conversion from a myogenic lineage to a fibroblastic 
one, which is consistent with a study from the Rando group (28). Moreover, inhibition of 
M-cadherin expression by RNAi reversed this effect, suggesting that M-cadherin-
mediated signaling is required by both myogenic differentiation and fibroblastic 
conversion induced by the activation of β-catenin/canonical Wnt signaling. This brings 
up a question, that is, will overexpression of M-cadherin in skeletal muscle lead to 
muscle fibrosis, which remains to be elucidated in a future study. On the other hand, 
although it is assumed that muscle fibrosis is a pathological procedure which has 
detrimental effects on the muscle quality and function, the mutual effects between 
myogenic myoblasts and fibroblasts during the process of myogenesis have drawn  
increasing attention and generated interesting observations. Emerging evidence from 
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different groups have shown that in addition to its classical role in adult muscle structure 
and function, connective tissue is an important component of the niche where muscle 
progenitors reside and is a critical regulator of myogenesis (29; 30). The mutual 
interactions between fibroblasts and satellite cells promote an efficient, effective 
myogenic differentiation (29-31).  
              In conclusion, the data presented in this dissertation demonstrates that M-
cadherin plays a critical role in regulating the fate of myoblasts by promoting their 
survival against mitochondria-associated intrinsic apoptosis during myogenic 
differentiation via PI3K/Akt/GSK-3β pathway. Furthermore, by modulating the 
phosphorylation status of β-catenin N-terminus, M-cadherin regulates β-
catenin/canonical Wnt signaling in a TCF/LEF-independent manner which is crucial for 
myogenic differentiation (Figure 23). These findings identify a novel mechanism 
underling the regulation of myoblast’s behavior and fate during muscle regeneration. 
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          Figure 23. Schematic summary of the regulatory role of M-cadherin in  
          myoblast’s apoptosis/survival and myogenic differentiation.  
          “     ” in the figure suggests that certain phosphorylation substrates of GSK-3β  
          that are involved In the occurrence of MOMP, such as Bax (32), are not  
          included in this figure since they are beyond  the scope of this dissertation. 
             
4.2. Significance of the findings and practical implications for treatment of 
human diseases.  
Decrease in both number and functionality of satellite cells is among the major 
contributing factors to the onset and progress of sarcopenia (33). In aged muscle, the 
number of M-cadherin-positive satellite cells is also lower (34).  Prior to the data 
presented in this dissertation, it was not known whether there is a correlation between a 
decreased M-cadherin expression and the decline in both number and function of 
satellite cells in aged muscle. The data in the present study demonstrates that M-
cadherin promotes myoblast’s differentiation and reduces apoptotic signaling by 
suppressing GSK-3β activity and enhancing β-catenin signaling activity. In contrast to 
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cadherin signaling outcomes in many other cell types, this observation supports a novel 
hypothesis that the disruption of M-cadherin-mediated cell-cell and cell-niche adhesions 
could be a possible mechanism that contributes to the decreased number and function 
of satellite cells in aged muscle, which gives rise to the onset and progression of 
sarcopenia and other muscle wasting disorders. The implications of the findings in this 
study are that gene overexpression of M-cadherin in aged muscle might be used as a 
potential therapeutic intervention that could rescue or at least partially attenuate the 
decrease in both number and functionality of satellite cells in aged muscle since 
enhanced M-cadherin-mediated signaling would provide signals that promote the 
survival and myogenic capability of satellite cells in aged muscle.  
 
Cadherins are an important component of the stem cell niche and have been 
reported to play a critical role in mediating the recruitment and adhesion of stem cells to 
their niche (35-38). A niche to stem cells is an anatomic residence for the cells to stay 
in. But more importantly, it is also a functional dimension that enables the cells to 
reproduce, self-renew, and survive in a stressful environment (39). Data from the 
current project could be eventually used to support therapies for muscular dystrophy. 
For example, in current experimental approaches or clinical trials that muscle progenitor 
cells or stem cells from other lineages are transplanted into a host with muscular 
dystrophic disorders such as Duchene Muscular Dystrophy, the low survival and 
engraftment rate of donor progenitor cells after transplantation has been a major barrier 
to the full success of this stem-cell-based therapies (40; 41). In addition, the in vitro 
handling and expansion of the donor cells before transplantation also decrease the in 
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vivo myogenic capability of the cells dramatically after they are injected into the host 
muscles (42; 43). Thus, either in vitro culture or injection of the cells into the host sites 
as foreign grafts may cause the loss of the original signals from the niche that promote 
survival and myogenic capability of the cells because the regular biological niche 
becomes temporarily or permanently unavailable to the transplanted cells. This could be 
an important contributing factor to the low survival and engraftment rate, as well as the 
poor myogenic performance, of the cells after transplantation. The survival- and 
myogenic promoting effect of M-cadherin demonstrated in this study provides a 
potential novel therapeutic approach. We propose that by increasing the gene 
expression of M-cadherin in the donor cells and the niches in host muscles, the survival 
and engraftment rate of cells after transplantation in muscle tissue will be improved, and 
the myogenic capability of the transplanted cells will also be increased. Thus the 
therapeutic outcome of the stem cell-based strategies in treating muscular dystrophies 
will be greatly improved. More importantly, this M-cadherin-overexpression hypothesis 
demonstrates the crucial role of a healthy niche in maintaining the survival, self-
expansion, and myogenic capability of muscle stem cells, not only for their survival and 
engraftment in vivo, but also during the process of expansion in vitro. The cells are 
isolated from the donor body and cultured in vitro to expand into enough number before 
they are ready to be injected into the host muscles. However, instead of culturing in a 
traditional cell culture system, an artificially modified and engineered culture system 
which is enriched with M-cadherin and other key adhesion molecules that are found in a 
stem cell niche should be used for cell culture. It might be able to help the isolated stem 
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cells maintain their myogenic capability before transplantation. The potential to alter the 
stem cell niche has attracted much recent attention from stem cell biologists (44; 45). 
 
In the present study, we demonstrate that M-cadherin-mediated signaling 
suppresses GSK-3β activation, promotes β-catenin/canonical Wnt signaling, and plays 
a positive role in maintaining the mitochondrial integrity in myoblasts during myogenic 
differentiation. Since both GSK-3β and mitochondria play a crucial role in glucose 
metabolism, the regulation of M-cadherin on both could have profound effects on the 
glucose metabolism and insulin sensitivity of muscle tissues. Thus, it is possible that 
increased expression of M-cadherin may be a potential therapy to reduce the effects of 
metabolic syndrome or diabetes. Our speculation here is in concert with studies from 
various groups: Ectopic expression of M-cadherin was found in the liver of KK/Ta 
mouse, which is an established animal model for type 2 diabetes (46); E-cadherin may 
regulate insulin secretion by modulating the intercellular communication between β-cells 
within pancreatic islets (47; 48); In addition, activation of Wnt signaling promotes 
mitochondrial biogenesis and regulates insulin sensitivity in C2C12 myoblasts (49). 
Although therapeutic applications of the results of this study are likely several years 
away, the data we present in this study cast M-cadherin in a new role as a potential 
metabolism regulator, and therefore a potential therapy for addressing diabetes and/or 
the metabolic syndrome. 
 
           4.3. Future studies. Although we demonstrated that M-cadherin-mediated 
signaling plays a critical role in regulating myoblast fate and biological behavior in the 
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research that we completed in Chapter 2 and 3, there are still many questions that 
remain to be elucidated.  
         Firstly, we showed that M-cadherin promotes β-catenin/canonical Wnt signaling-
mediated myogenic differentiation in a TCF/LEF-independent manner.  Based on the 
studies from other groups, MRFs such as MyoD, as well as a MRF-regulatory protein I-
mfa, could be the candidates that mediate the TCF/LEF-independent myogenic 
induction effect by M-cadherin/β-catenin signaling. It has been shown that β-catenin 
interacts directly with MyoD and this interaction promotes MyoD transcription activity  
(50)  and the binding of β-catenin to I-mfa relieves its inhibition to MRFs (51). To further 
identify the downstream target for M-cadherin/β-catenin signaling, primary muscle 
progenitor cells could be isolated from hind limb muscles of wild-type mice. The change 
in gene expression level of MRFs and I-mfa could then be examined in cells treated with 
either M-cadherin RNAi or recombinant M-cadherin-Fc, to find out if the gene 
expression of any MRF and I-mfa are responsive to the manipulation of M-cadherin-
mediated signaling. Additionally, the co-immunoprecipitation of β-catenin with MRFs 
and I-mfa could be performed to examine the change in interactions between β-catenin 
and MRFs and I-mfa in response to the manipulation of M-cadherin–mediated signaling. 
Furthermore, the gene expression of MRFs and I-mfa could be manipulated by 
overexpression or knockdown techniques to see which one could rescue the myogenic 
phenotype caused by M-cadherin RNAi. By doing so, the role of MRFs and I-mfa in 
mediating M-cadherin/β-catenin’s myogenesis-inducing effect will be clarified (Figure 
24). 
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          Secondly, one of the ultimate approaches is to establish a muscle-specific M-
cadherin overexpression transgenic mouse model. The M-cadherin cDNA could be 
cloned into a transgenic vector plasmid driven by a muscle-specific muscle creatine 
kinase (MCK) promoter (52). The chimeric transgene should then be purified and used 
for generation of muscle-specific transgenic mice. Upon successful generation, the 
transgenic mice and the control ones with same genetic background should be used for 
following two sets of experiments. First set: cardiotoxin could be injected into the hind 
limb muscles of either the young or old, M-cadherin-overexpressing transgenic or wild-
type (WT) mice, to cause muscle injury. One to two weeks after cardiotoxin injection, 
the injured muscles could then be dissected and markers for muscle regeneration and 
fibrosis could be analyzed and compared among young and old, M-cadherin-
overexpressing and WT mice (Figure 25). In the second set of experiments, satellite 
cells could be isolated from the hind limb muscles of either M-cadherin-overexpressing 
or WT 2-week-old mice for in vitro culture. Myogenic differentiation could then be 
induced and markers for apoptosis, myogenesis, and fibrosis will be measured and 
compared between M-cadherin-overexpressing transgenic and WT cells (Figure 25). 
Through these proposed experiments, the findings from in vitro cell culture work that M-
cadherin protects myoblasts against apoptosis and promotes myogenic differentiation 
will be verified at a gross muscle level in an animal system. These proposed studies 
could allow future students to clarify the role of M-cadherin in regulating adult muscle 
regeneration.  
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              Figure 24. Outline of the strategies to clarify the role of MRFs   
              and I-mfa in mediating M-cadherin/β-catenin’s promoting effect  
              on myogenic differentiation.  
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        Figure 25. Outline of the strategies to examine the capability of muscle  
        regeneration and fibrosis potential of M-cadherin (M-cad)-overexpression  
        transgenic mouse in response to muscle injury, and the in vitro  
        myogenic capability of satellite cells isolated from the transgenic mice.  
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